image_name stringlengths 68 68 | type stringclasses 2
values | gt_table stringlengths 116 12.6k | table_fragment_1 stringlengths 43 8.42k | table_fragment_2 stringlengths 39 8.21k |
|---|---|---|---|---|
26cc285aac7120c2adaf25b6c38baaac6cf226850b578a6a477b3f631ac18c02.png | complex | <table><tr><td rowspan="3">Variables</td><td>Overall</td><td rowspan="3"><i>p</i>-Value</td><td>Women</td><td rowspan="3"><i>p</i>-Value</td><td>Men</td><td rowspan="3"><i>p</i>-Value</td></tr><tr><td>N = 7504</td><td>N = 766</td><td>N = 6738</td></tr><tr><td>OR (95% CI)</td><td>OR (95% CI)</td><td>OR (95% CI)</td></tr... | <table><tr><td rowspan="3">Variables</td><td>Overall</td><td rowspan="3">p-Value</td><td>Women</td><td rowspan="3">p-Value</td><td>Men</td><td rowspan="3">p-Value</td></tr><tr><td>N = 7504</td><td>N = 766</td><td>N = 6738</td></tr><tr><td>OR (95% CI)</td><td>OR (95% CI)</td><td>OR (95% CI)</td></tr><tr><td>Age (by five... | <table><tr><td>FPG ≥ 100 mg/dL</td><td>1.94 (1.63–2.30)</td><td><0.0001</td><td>12.64 (4.34–36.8)</td><td><0.0001</td><td>1.74 (1.46–2.07)</td><td><0.0001</td></tr><tr><td>Low serum HDL $</td><td>2.60 (2.24–3.02)</td><td><0.0001</td><td>2.93 (1.08–7.91)</td><td>0.034</td><td>2.72 (2.33–3.17)</td><td><0.0001</td></tr><t... |
e5dacfbd215abbdad8acc9106bb7f36c537ad089a8659dc0e45400e787639349.png | simple | <table><tr><td>Antibody (host, clonality, Company)</td><td>Purpose</td><td>Dilution</td></tr><tr><td>FGFR1 (rabbit, polyclonal, Santa Cruz Biotechnology, CA)</td><td>IHC</td><td>1:150</td></tr><tr><td>FGFR2 (rabbit, polyclonal, Santa Cruz Biotechnology, CA)</td><td>IHC</td><td>1:150</td></tr><tr><td>FGF7 (rabbit, polyc... | <table><tr><td>Antibody (host, clonality, Company)</td><td>Purpose</td><td>Dilution</td></tr><tr><td>FGFR1 (rabbit, polyclonal, Santa Cruz Biotechnology, CA)</td><td>IHC</td><td>1:150</td></tr><tr><td>FGFR2 (rabbit, polyclonal, Santa Cruz Biotechnology, CA)</td><td>IHC</td><td>1:150</td></tr><tr><td>FGF7 (rabbit, polyc... | <table><tr><td>Antibody (host, clonality, Company)</td><td>Purpose</td><td>Dilution</td></tr><tr><td>FGF10 (goat, polyclonal, Peprotech Inc., Rocky Hill, NJ)</td><td>WB</td><td>1:200</td></tr><tr><td>p-p44/42 MAPK (Thr202/Tyr204) (rabbit, polyclonal, Cell Signaling, Beverly, MA)</td><td>WB</td><td>1:1,000</td></tr><tr>... |
16abdcae8b6427d58acf6294fe25b8c288d0307d6f775878cbfccce185e5e248.png | complex | <table><tr><td><i>N</i> = 54</td><td colspan="4">Test site</td></tr><tr><td></td><td>A</td><td>C2</td><td>L</td><td>C1</td></tr><tr><td>Average speed (km.h<sup>−1</sup>)</td><td>23.1 ± 1.3a<sup>*</sup></td><td>21.1 ± 1.0b</td><td>21.2 ± 0.8b</td><td>22.4 ± 0.9a</td></tr><tr><td>HR (beats.mn<su... | <table><tr><td>N = 54</td><td colspan="4">Test site</td></tr><tr><td></td><td>A</td><td>C2</td><td>L</td><td>C1</td></tr><tr><td>Average speed (km.h−1)</td><td>23.1 ± 1.3a*</td><td>21.1 ± 1.0b</td><td>21.2 ± 0.8b</td><td>22.4 ± 0.9a</td></tr><tr><td>HR (beats.mn−1)</td><td>142.2 ± 15.2</td><td>140.0 ± 9.3</td><td>141.2... | <table><tr><td>N = 54</td><td colspan="4">Test site</td></tr><tr><td></td><td>A</td><td>C2</td><td>L</td><td>C1</td></tr><tr><td>u (%)</td><td>39.9 ± 11.8</td><td>7 ± 8.9</td><td>51.6 ± 15.7</td><td>.0 ± 14.4</td></tr></table> |
c72350f30549b497fec1c67d5a7d971cb6844e96c9db200ad02997d79d4451a2.png | simple | <table><tr><td>Characteristics</td><td>Controls n = 67</td><td>NSTEMI n = 38</td><td>STEMI n = 30</td></tr><tr><td>Age</td><td>66 ± 12</td><td>72 ± 15</td><td>72 ± 13</td></tr><tr><td>M/F</td><td>46/21</td><td>29/9</td><td>21/9</td></tr><tr><td>Diabetes Mellitus</td><td>8</td><td>8</td><td>4</td></tr><tr... | <table><tr><td>Characteristics</td><td>Controls n = 67</td></tr><tr><td>Age</td><td>66 ± 12</td></tr><tr><td>M/F</td><td>46/21</td></tr><tr><td>Diabetes Mellitus</td><td>8</td></tr><tr><td>Prior IHD</td><td>29</td></tr><tr><td>Hemoglobine, g/l</td><td>135 ± 15</td></tr><tr><td>Platelet count, ×109/l</td><td>224 ± 74</t... | <table><tr><td>NSTEMI n = 38</td><td>STEMI n = 30</td></tr><tr><td>72 ± 15</td><td>72 ± 13</td></tr><tr><td>29/9</td><td>21/9</td></tr><tr><td>8</td><td>4</td></tr><tr><td>18</td><td>12</td></tr><tr><td>132 ± 15</td><td>132 ± 16</td></tr><tr><td>218 ± 51</td><td>222 ± 66</td></tr><tr><td>4,67 ± 0,94</td><td>4,60 ± 0,79... |
b271cb0457b1b5ffb5a0e9e347c662a6813c491c1415d74b01e8e6d4e80b5711.png | simple | <table><tr><td>Raw material</td><td>Cellulose</td><td>Hemicellulose</td><td>Lignin</td><td>Ash</td></tr><tr><td>Wheat straw</td><td>44.2 (1.8)</td><td>26.5 (1.9)</td><td>22.4 (1.7)</td><td>2.8 (0.6)</td></tr><tr><td>Rice straw</td><td>36.1 (2.6)</td><td>27.2 (3.2)</td><td>19.7 (2.5)</td><td>12.1 (2.8)</td></tr><tr><td>... | <table><tr><td>Raw material</td><td>Cellulose</td><td>Hemicellulose</td><td>Lignin</td><td>Ash</td></tr><tr><td>Wheat straw</td><td>44.2 (1.8)</td><td>26.5 (1.9)</td><td>22.4 (1.7)</td><td>2.8 (0.6)</td></tr></table> | <table><tr><td>Raw material</td><td>Cellulose</td><td>Hemicellulose</td><td>Lignin</td><td>Ash</td></tr><tr><td>Rice straw</td><td>36.1 (2.6)</td><td>27.2 (3.2)</td><td>19.7 (2.5)</td><td>12.1 (2.8)</td></tr><tr><td>Poplar</td><td>39.2 (1.1)</td><td>18.8 (1.4)</td><td>29.6 (1.6)</td><td>1.5 (1.2)</td></tr></table> |
9afba184dea57942fc96ec313852f15774d9553984e735a2ec7290c4ddfc0834.png | complex | <table><tr><td colspan="4"></td><td colspan="5">Up/Down-regulated<sup>c</sup></td><td colspan="3">Regulated by</td></tr><tr><td></td><td>Gene<sup>a</sup></td><td>Enzyme<sup>b</sup></td><td>CAZy family</td><td>Δ<i>xlnR</i></td><td>Δ<i>araR</i></td><td>Δ<i>rhaR</i></td><td>Δ<i>galX</i></td><td>Δ<... | <table><tr><td colspan="3"></td></tr><tr><td></td><td>Genea</td><td>Enzymeb</td></tr><tr><td rowspan="2">E-1</td><td>An15g04900 (eglD)</td><td>LPMO</td></tr><tr><td>An03g00190 (pelB)</td><td>PEL</td></tr><tr><td rowspan="6">E-2</td><td>An07g09760</td><td>BGL</td></tr><tr><td>An08g01100</td><td>EXG</td></tr><tr><td>An11... | <table><tr><td></td><td colspan="5">Up/Down-regulatedc</td><td colspan="3">Regulated by</td></tr><tr><td>CAZy family</td><td>ΔxlnR</td><td>ΔaraR</td><td>ΔrhaR</td><td>ΔgalX</td><td>ΔamyR</td><td>This study</td><td>Literature</td><td>Reference</td></tr><tr><td>AA9</td><td>2.1</td><td>−1.2</td><td>−1.7</td><td>−1.6</td><... |
5c1a90fe2818afd05eeb8cdbe09cf1fe9db826fda7d7b417a883bba21d744777.png | complex | <table><tr><td>Year</td><td colspan="2">Public Hospitals</td><td>Public medic patients</td></tr><tr><td></td><td>Outpatients (95% CI)</td><td># of hospitalizations</td><td></td></tr><tr><td>1918</td><td>20.11 (16.43, 25.90)</td><td>12.20 (10.59, 14.38)</td><td>32.21* (28.48, 39.82)</td></tr><tr><td>1919</td><td>14.55 (... | <table><tr><td>Year</td><td colspan="2">Public Hospitals</td><td>Public medic patients</td></tr><tr><td></td><td>Outpatients (95% CI)</td><td># of hospitalizations</td><td></td></tr></table> | <table><tr><td>1918</td><td>20.11 (16.43, 25.90)</td><td>12.20 (10.59, 14.38)</td><td>32.21* (28.48, 39.82)</td></tr><tr><td>1919</td><td>14.55 (11.89, 18.74)</td><td>36.70* (31.85, 43.27)</td><td>26.64* (22.70, 31.73)</td></tr><tr><td>1920</td><td>1.72 (1.40, 2.21)</td><td>19.83* (17.21, 23.38)</td><td>8.27 (7.09, 9.9... |
fd1164931ece75cada74d5df26877423f27210e5f7ef6ebcb2c5b89332d91480.png | complex | <table><tr><td colspan="2">Surface material</td><td>SBS</td><td>ARI</td></tr><tr><td rowspan="3">Enamel</td><td>Chi-square test</td><td>18.512</td><td>11.686</td></tr><tr><td> Df</td><td>2</td><td>2</td></tr><tr><td>Asymptotic significance</td><td>0.000</td><td>0.003</td></tr><tr><td rowspan="3">SR Adoro</td><td>Chi-sq... | <table><tr><td colspan="2">Surface material</td><td>SBS</td><td>ARI</td></tr><tr><td rowspan="3">Enamel</td><td>Chi-square test</td><td>18.512</td><td>11.686</td></tr><tr><td>Df</td><td>2</td><td>2</td></tr><tr><td>Asymptotic significance</td><td>0.000</td><td>0.003</td></tr><tr><td rowspan="3">SR Adoro</td><td>Chi-squ... | <table><tr><td colspan="2">Surface material</td><td>SBS</td><td>ARI</td></tr><tr><td>e.max Press</td><td>Asymptotic significance</td><td>0.000</td><td>0.003</td></tr><tr><td rowspan="3">ZirCAD</td><td>Chi-square test</td><td>16.423</td><td>15.612</td></tr><tr><td>Df</td><td>2</td><td>2</td></tr><tr><td>Asymptotic signi... |
54489499a55fdf9487d86a179e00ededa3e3dcfa4f19216798a609ca6ec25cde.png | complex | <table><tr><td>Year</td><td>Number of districts</td><td colspan="2">Districts reporting at least one suspected case</td><td>Number of suspected cases reported</td><td colspan="2">Blood specimens collected</td><td colspan="2">Confirmed cases</td><td>Districts with confirmed cases</td></tr><tr><td></td><td><i>n</i></td><... | <table><tr><td>Year</td><td>Number of districts</td><td colspan="2">Districts reporting at least one suspected case</td><td>Number of suspected cases reported</td><td colspan="2">Blood specimens collected</td><td colspan="2">Confirmed cases</td><td>Districts with confirmed cases</td></tr><tr><td></td><td>n</td><td>n</t... | <table><tr><td>2006</td><td>167</td><td>114</td><td>68.2</td><td>859</td><td>859</td><td>100</td><td>1</td><td>0.2</td><td>Messamena</td></tr></table> |
b121cc95893795522ef766b13edb6863fb6a407a2bb16326e454798f54842672.png | complex | <table><tr><td rowspan="2">Variable</td><td>Univariate</td><td colspan="2">Multivariate</td></tr><tr><td><i>p</i> value</td><td><i>p</i> value</td><td>HR (95% CI)</td></tr><tr><td>Male gender</td><td><0.0001</td><td>0.0104</td><td>1.42 (1.08–1.85)</td></tr><tr><td>Age > 55 years</td><td><0.0001</td><td>&... | <table><tr><td rowspan="2">Variable</td><td>Univariate</td><td colspan="2">Multivariate</td></tr><tr><td>p value</td><td>p value</td><td>HR (95% CI)</td></tr></table> | <table><tr><td>Male gender</td><td><0.0001</td><td>0.0104</td><td>1.42 (1.08–1.85)</td></tr><tr><td>Age > 55 years</td><td><0.0001</td><td><0.0001</td><td>8.33 (6.49–10.75)</td></tr><tr><td>Distant metastasis (M1)</td><td><0.0001</td><td><0.0001</td><td>6.06 (3.92–9.35)</td></tr><tr><td>Extrathyroid extension (Ex)</td>... |
439647234f2348fe499a423928fb1e0abd4e8357d6465fb83637f700468ef418.png | simple | <table><tr><td>Type of ZnO nanostructure</td><td>Turn-on field (V μm<sup>-1</sup>)</td><td>Threshold field (V μm<sup>-1</sup>)</td><td><i>β</i></td></tr><tr><td>Leaf-like (30 min)</td><td>2.94</td><td>4.35</td><td>2,800</td></tr><tr><td>Long NWs arrays (60 min)</td><td>3.69</td><td>5.72</td><td>2,526</td... | <table><tr><td>Type of ZnO nanostructure</td><td>Turn-on field (V μm-1)</td><td>Threshold field (V μm-1)</td><td>β</td></tr></table> | <table><tr><td>Leaf-like (30 min)</td><td>2.94</td><td>4.35</td><td>2,800</td></tr><tr><td>Long NWs arrays (60 min)</td><td>3.69</td><td>5.72</td><td>2,526</td></tr><tr><td>Needle-like</td><td>3.87</td><td>5.65</td><td>2,284</td></tr></table> |
b7180e1705f50266cc9bcfabcaee0466d43a2ab98264b87b0a131518429493cd.png | simple | <table><tr><td>Patient no.</td><td>CSF leakage</td><td>Leakage pattern</td><td>Location of CSF leakage</td><td>Exact location of CSF leakage</td></tr><tr><td>1</td><td>+</td><td>Pseudodiverticular</td><td>Left T11/12</td><td>+</td></tr><tr><td>2</td><td>+</td><td>Gray rim</td><td>L1</td><td>+</td></tr><tr><td>3</td><td... | <table><tr><td>Patient no.</td></tr><tr><td>1</td></tr><tr><td>2</td></tr><tr><td>3</td></tr><tr><td>4</td></tr><tr><td>5</td></tr><tr><td>6</td></tr><tr><td>7</td></tr><tr><td>8</td></tr><tr><td>9</td></tr><tr><td>10</td></tr><tr><td>11</td></tr><tr><td>12</td></tr><tr><td>13</td></tr><tr><td>14</td></tr><tr><td>15</t... | <table><tr><td>CSF leakage</td><td>Leakage pattern</td><td>Location of CSF leakage</td><td>Exact location of CSF leakage</td></tr><tr><td>+</td><td>Pseudodiverticular</td><td>Left T11/12</td><td>+</td></tr><tr><td>+</td><td>Gray rim</td><td>L1</td><td>+</td></tr><tr><td>−</td><td></td><td>−</td><td>−</td></tr><tr><td>+... |
2cf21bf0cbb132b0ce0512fe3344666f7f1a1bfafb0f3b19a18937884535b235.png | complex | <table><tr><td colspan="2">Variable</td><td>MetS= Yes, n (%)</td><td>COR (95% CI)</td><td><i>P-value</i></td><td>AOR (95% CI)</td><td><i>P-value</i></td></tr><tr><td rowspan="2">Gender</td><td>Men</td><td>44 (37.9)</td><td>1.00</td><td></td><td>1.00</td><td></td></tr><tr><td>women</td><td>72 (62.1)</td><td>1.6 (0.97... | <table><tr><td colspan="2">Variable</td></tr><tr><td rowspan="2">Gender</td><td>Men</td></tr><tr><td>women</td></tr><tr><td rowspan="2">Residence:</td><td>Rural</td></tr><tr><td>Urban</td></tr><tr><td rowspan="4">Age in years:</td><td>≤30</td></tr><tr><td>31–45</td></tr><tr><td>46–60</td></tr><tr><td>≥61</td></tr><tr><... | <table><tr><td>MetS= Yes, n (%)</td><td>COR (95% CI)</td><td>P-value</td><td>AOR (95% CI)</td><td>P-value</td></tr><tr><td>44 (37.9)</td><td>1.00</td><td></td><td>1.00</td><td></td></tr><tr><td>72 (62.1)</td><td>1.6 (0.97–2.74)</td><td>0.06</td><td>1.7 (0.66–4.4)</td><td>0.27</td></tr><tr><td>20 (17.2)</td><td>1.00</td... |
77d3421194461b57440ab105601490b917c8d5be535aa073767a283cba3064fa.png | complex | <table><tr><td rowspan="2">Instrument</td><td colspan="2">Unprepared apical area (%)</td><td colspan="2">Unprepared coronal area (%)</td></tr><tr><td>Mean ± SD</td><td>Min-Max</td><td>Mean ± SD</td><td>Min-Max</td></tr><tr><td>ProTaper Next</td><td>11.03 ± .96</td><td>10.11–12.8</td><td>55.70 ±... | <table><tr><td rowspan="2">Instrument</td></tr><tr></tr><tr><td>ProTaper Next</td></tr><tr><td>WaveOne</td></tr><tr><td>P value</td></tr></table> | <table><tr><td colspan="2">Unprepared apical area (%)</td><td colspan="2">Unprepared coronal area (%)</td></tr><tr><td>Mean ± SD</td><td>Min-Max</td><td>Mean ± SD</td><td>Min-Max</td></tr><tr><td>11.03 ± .96</td><td>10.11–12.8</td><td>55.70 ± 1.25</td><td>53.26–57.19</td></tr><tr><td>12.06 ± 1.21</td><td>9.25–13.10</td... |
71a0f3fcdc8f3a61c6d345f8e3fc06afd30e7392315e793901893564cdc7feb5.png | simple | <table><tr><td>Heart evaluation parameters</td><td>CRT</td><td>IMRT</td></tr><tr><td>Average maximum heart dose (cGy)</td><td>5295.26</td><td>5209.87</td></tr><tr><td>Range (cGy)</td><td>4858.3–5743.8</td><td>4895.17–5862.8</td></tr><tr><td><i>P-</i>value</td><td>0.08</td><td>0.08</td></tr></table> | <table><tr><td>Heart evaluation parameters</td><td>CRT</td><td>IMRT</td></tr><tr><td>Average maximum hear</td><td>52</td><td>52</td></tr></table> | <table><tr><td>t dose (cGy)</td><td>95.26</td><td>09.87</td></tr><tr><td>Range (cGy)</td><td>4858.3–5743.8</td><td>4895.17–5862.8</td></tr><tr><td>P-value</td><td>0.08</td><td>0.08</td></tr></table> |
e00918e7dcf1572b21b27f9a21d339ade2978aaea448ab4a51dce5e211961190.png | complex | <table><tr><td></td><td>All studies (<i>n </i>=<i> </i>102)</td><td>Randomized trials (<i>n </i>=<i> </i>25)</td><td>Nonrandomized studies (<i>n </i>=<i> </i>77)</td></tr><tr><td>Number of participants</td><td>66 386</td><td>7172</td><td>59 214</td></tr><tr><td>Age range of participants (years)</td><td>18–99</td>... | <table><tr><td></td></tr><tr><td>Number of participants</td></tr><tr><td>Age range of participants (years)</td></tr><tr><td>Number of participating centres (%)</td></tr><tr><td>Single</td></tr><tr><td>Multiple</td></tr><tr><td>IRB or ethical approval reported (%)</td></tr><tr><td>Tumour site (%)</td></tr><tr><td>Colon<... | <table><tr><td>All studies (n = 102)</td><td>Randomized trials (n = 25)</td><td>Nonrandomized studies (n = 77)</td></tr><tr><td>66 386</td><td>7172</td><td>59 214</td></tr><tr><td>18–99</td><td>29–89</td><td>18–99</td></tr><tr><td colspan="3">Number of participating centres (%)</td></tr><tr><td>58 (57)</td><td>13 (52)<... |
f7a5eae316d8b0e3579dcf8e6b0d2a98593584c05accd3654a4c7fe4f6c54a9b.png | complex | <table><tr><td></td><td colspan="2">Right</td><td><i>p</i></td><td colspan="2">Left</td><td><i>p</i></td></tr><tr><td></td><td>Female</td><td>Male</td><td></td><td>Female</td><td>Male</td><td></td></tr><tr><td></td><td>Mean±SD</td><td>Mean±SD</td><td></td><td>Mean±SD</td><td>Mean±SD</td><td></td></t... | <table><tr><td></td><td colspan="2">Right</td><td>p</td><td colspan="2">Left</td><td>p</td></tr><tr><td></td><td>Female</td><td>Male</td><td></td><td>Female</td><td>Male</td><td></td></tr><tr><td></td><td>Mean±SD</td><td>Mean±SD</td><td></td><td>Mean±SD</td><td>Mean±SD</td><td></td></tr><tr><td>Cervical region</td><td>... | <table><tr><td></td><td colspan="2">Right</td><td>p</td><td colspan="2">Left</td><td>p</td></tr><tr><td></td><td>Female</td><td>Male</td><td></td><td>Female</td><td>Male</td><td></td></tr><tr><td></td><td>Mean±SD</td><td>Mean±SD</td><td></td><td>Mean±SD</td><td>Mean±SD</td><td></td></tr><tr><td>Long-axis diameter (mm)<... |
23b0c1acba3527d9b6ffb5a87effe5036b96a8e2647c74916e3a668d1aee8ee4.png | simple | <table><tr><td>Figure #</td><td>Algorithms Used</td><td>Initial Benefit</td><td>Acquired Benefit</td><td>Lost Benefit</td><td>Overall Distance</td><td>Solution Time (s)</td></tr><tr><td>11a</td><td>Greedy TA Heuristic MP</td><td>21,000</td><td>9479</td><td>11,521</td><td>2446</td><td>1.85</td></tr><tr><td>11b</td><td>G... | <table><tr><td></td><td>Al</td><td>Initial Benefit</td><td>Acquire</td><td>Lost</td><td>Over</td><td>Solution Tim</td></tr></table> | <table><tr><td>Figure #</td><td>gorithms Used</td><td></td><td>d Benefit</td><td> Benefit</td><td>all Distance</td><td>e (s)</td></tr><tr><td>11a</td><td>Greedy TA Heuristic MP</td><td>21,000</td><td>9479</td><td>11,521</td><td>2446</td><td>1.85</td></tr><tr><td>11b</td><td>Greedy TA Heuristic MP</td><td>21,000</td><td... |
1731c8b6f31af474866153f4d6e97ca664254c811d43a2ccf0ea5019c5043c80.png | simple | <table><tr><td>Construct</td><td>Transgene</td><td>Progeny</td><td>n</td></tr><tr><td></td><td><i>ebEx498</i></td><td>92 ± 16</td><td>11</td></tr><tr><td></td><td><i>xyEx175</i></td><td>123 ± 15</td><td>10</td></tr><tr><td></td><td><i>xyEx177</i></td><td>115 ± 17</td><td>11</td></tr><tr><td></td><td><i>x... | <table><tr><td>Construct</td><td>Transgene</td><td>Progeny</td><td>n</td></tr><tr><td></td><td>ebEx498</td><td>92 ± 16</td><td>11</td></tr><tr><td></td><td>xyEx175</td><td>123 ± 15</td><td>10</td></tr><tr><td></td><td>xyEx177</td><td>115 ± 17</td><td>11</td></tr><tr><td></td><td>xyEx1</td><td>2 ± 1</td><td>10</td></tr>... | <table><tr><td>Construct</td><td>Transgene</td><td>Progeny</td><td>n</td></tr><tr><td></td><td>xyEx30</td><td>8 ± 4</td><td>10</td></tr><tr><td></td><td>xyEx34</td><td>17 ± 4</td><td>10</td></tr><tr><td></td><td>xyEx36</td><td>83 ± 15</td><td>9</td></tr><tr><td></td><td>xyEx37</td><td>110 ± 10</td><td>8</td></tr><tr><t... |
a83a7c7b7e975d5191c15743a6f3263a746c73733efc9d8c09af515a75b51d4f.png | simple | <table><tr><td>Epigenetic discovery</td><td>Health promotion research innovation domains</td><td>Example translational research questions</td></tr><tr><td>Individual variation in whether risk exposures negatively influence gene expression</td><td>Improving motivational potency of health communications</td><td>Evaluatin... | <table><tr><td>Epigenetic discovery</td><td>Health promotion research innovation domains</td><td>Example translational research questions</td></tr><tr><td>Individual variation in whether risk exposures negatively influence gene expression</td><td>Improving motivational potency of health communications</td><td>Evaluatin... | <table><tr><td>Intervention adherence can prompt measurable gene expression</td><td>Intervention targeting and tailoring</td><td>Comparative effectiveness of targeting relapse prevention approach based on gene expression profile following intervention participation</td></tr><tr><td>New technology to measure epigenetic ... |
3bfe5d4510d5fea31b4eef28ed1789dcb1e162ecf59754dbed010751f335a6fc.png | simple | <table><tr><td></td><td>MCAA+</td><td>MCAA−</td><td>NHS</td><td>PLG+</td></tr><tr><td>Age (mean)</td><td>61.0</td><td>59.2</td><td>58.7</td><td>59.6</td></tr><tr><td>Age (SD)</td><td>10.5</td><td>13.3</td><td>3.7</td><td>12.3</td></tr><tr><td>M:F (ratio)</td><td>33:23 (1.43)</td><td>30: 21 (1.43)</td><td>25: 15 (... | <table><tr><td></td><td>MCAA+</td><td>MCAA−</td><td>NHS</td><td>PLG+</td></tr><tr><td>Age (mean)</td><td>61.0</td><td>59.2</td><td>58.7</td><td>59.6</td></tr></table> | <table><tr><td>Age (SD)</td><td>10.5</td><td>13.3</td><td>3.7</td><td>12.3</td></tr><tr><td>M:F (ratio)</td><td>33:23 (1.43)</td><td>30: 21 (1.43)</td><td>25: 15 (1.67)</td><td>27: 18 (1.5)</td></tr></table> |
d8f298055d3fd8949d8ab6134c61a4388b21a086019977d4ff71390d773f153e.png | simple | <table><tr><td>Patient</td><td>1</td><td>2</td><td>3</td></tr><tr><td>Age(year)</td><td>47</td><td>39</td><td>48</td></tr><tr><td>Follow-up(month)</td><td>70</td><td>54</td><td>5</td></tr><tr><td>Outcome</td><td>Favorable</td><td>Favorable</td><td>Favorable</td></tr><tr><td>Pre-operation upper-limb blood pressure(mm Hg... | <table><tr><td>Patient</td><td>1</td><td>2</td><td>3</td></tr><tr><td>Age(year)</td><td>47</td><td>39</td><td>48</td></tr><tr><td>Follow-up(month)</td><td>70</td><td>54</td><td>5</td></tr><tr><td>Outcome</td><td>Favorable</td><td>Favorable</td><td>Favorable</td></tr><tr><td>Pre-operation upper-limb blood pressure(mm Hg... | <table><tr><td>Patient</td><td>1</td><td>2</td><td>3</td></tr><tr><td>Post-operation upper-limb blood pressure(mm Hg)</td><td>125/65</td><td>125/80</td><td>130/80</td></tr><tr><td>Post-operation lower-limb blood pressure(mm Hg)</td><td>130/70</td><td>130/80</td><td>130/75</td></tr></table> |
5609a019bf06a6edc758e8e15563f95850f5fae289ff12398230aa2443bd8c63.png | complex | <table><tr><td>Characteristic<sup>§</sup></td><td colspan="5">Levels of sCD40L</td></tr><tr><td></td><td colspan="2">High</td><td colspan="2">Medium-Low</td><td>p</td></tr><tr><td></td><td>No.</td><td>(%)</td><td>No.</td><td>%</td><td></td></tr><tr><td>Age:</td><td></td><td></td><td></td><td></td><td></td></tr><tr... | <table><tr><td>Characteristic§</td><td colspan="5">Levels of sCD40L</td></tr><tr><td></td><td colspan="2">High</td><td colspan="2">Medium-Low</td><td>p</td></tr><tr><td></td><td>No.</td><td>(%)</td><td>No.</td><td>%</td><td></td></tr></table> | <table><tr><td>Characteristic§</td><td colspan="5">Levels of sCD40L</td></tr><tr><td>Age:</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><= 39</td><td>8</td><td>(40.0)</td><td>8</td><td>(20.0)</td><td></td></tr><tr><td>40–54</td><td>9</td><td>(45.0)</td><td>14</td><td>(35.0)</td><td></td></tr><tr><td>>= ... |
30ebd356f36b9bbfe358ead734e61b2f9ed5688151b19e41a7ab56a8f1ec36ee.png | simple | <table><tr><td></td><td>df</td><td>AIC</td><td>BIC</td><td>logLik</td></tr><tr><td>m.rel.index</td><td>8</td><td>2043373</td><td>2043457</td><td>−1021678</td></tr><tr><td>m.freq.index</td><td>8</td><td>2043326</td><td>2043410</td><td>−1021655</td></tr></table> | <table><tr><td></td><td>df</td><td>AIC</td><td>BIC</td><td>logLik</td></tr><tr><td>m.rel.index</td><td>8</td><td>2043373</td><td>2043457</td><td>−1021678</td></tr></table> | <table><tr><td></td><td>df</td><td>AIC</td><td>BIC</td><td>logLik</td></tr><tr><td>m.freq.index</td><td>8</td><td>2043326</td><td>2043410</td><td>−1021655</td></tr></table> |
485c93a03463d6148659e430dfd854d05a1a5f15199cba49a8a8825b7695c100.png | simple | <table><tr><td>Time point (min)</td><td>42.5</td><td>47.5</td><td>52.5</td><td>57.5</td><td>62.5</td><td>72.5</td><td>72.5</td><td>77.5</td><td>82.5</td><td>87.5</td></tr><tr><td>Bias (%)</td><td>53</td><td>46</td><td>40</td><td>32</td><td>25</td><td>22</td><td>18</td><td>12</td><td>9</td><td>0</td></tr><tr><td>Factor ... | <table><tr><td>Time point (min)</td><td>42.5</td><td>47.5</td><td>52.5</td><td>57.5</td><td>62.5</td><td>72.5</td><td>72.5</td><td>77.5</td><td>82.5</td><td>87.5</td></tr><tr><td>Bias</td><td>5</td><td>4</td><td>40</td><td></td><td>2</td><td></td><td></td><td>12</td><td>9</td><td></td></tr></table> | <table><tr><td> (%)</td><td>3</td><td>6</td><td></td><td>32</td><td>5</td><td>22</td><td>18</td><td></td><td></td><td>0</td></tr><tr><td>Factor 1</td><td>0.877</td><td>0.898</td><td>0.977</td><td>0.973</td><td>0.967</td><td>0.986</td><td>0.963</td><td>0.975</td><td>0.843</td><td>0.8573</td></tr><tr><td>Factor 2</td><td... |
6b459829f1d98533908472c6ec8a3522581da62849302bfd426afc7d49dc4fee.png | complex | <table><tr><td>Characteristic</td><td>Number (%)</td></tr><tr><td colspan="2">Age(months)</td></tr><tr><td> 0–11</td><td>166(24.3%)</td></tr><tr><td> 12–23</td><td>189(27.7%)</td></tr><tr><td> 24–35</td><td>101(14.7%)</td></tr><tr><td> 36–47</td><td>116(16.9%)</td></tr><tr><td> 48–59</td><... | <table><tr><td>Characteristic</td><td>Number (%)</td></tr><tr><td colspan="2">Age(months)</td></tr><tr><td>0–11</td><td>166(24.3%)</td></tr><tr><td>12–23</td><td>189(27.7%)</td></tr><tr><td>24–35</td><td>101(14.7%)</td></tr><tr><td>36–47</td><td>116(16.9%)</td></tr><tr><td>48–59</td><td>112(16.4%)</td></tr><tr><td cols... | <table><tr><td>Characteristic</td><td>Number (%)</td></tr><tr><td colspan="2">Season</td></tr><tr><td>Spring(January–March)</td><td>161(23.5%)</td></tr><tr><td>Summer(April–June)</td><td>252(36.8%)</td></tr><tr><td>Autumn(July–September)</td><td>123(18.0%)</td></tr><tr><td>Winter(October–December)</td><td>148(21.6%)</t... |
263963797e794ce3ead9b00ce3e9f99b99dab26c0e052e7438403b48f4b01faf.png | complex | <table><tr><td> </td><td>Serology (serologicmarkers)<sup><i>∗</i></sup></td><td>Endoscopy of duodenum (mucosal morphologic alternations<sup><i>∗∗</i></sup>)</td><td>Genotype (genetic markers)</td></tr><tr><td rowspan="4"> </td><td>IgA anti-tissue transglutaminase antibodies (IgA anti-tTG, IgG anti-tTG... | <table><tr><td></td><td>Serology (serologicmarkers)∗</td><td>Endoscopy of duodenum (mucosal morphologic alternations∗∗)</td><td>Genotype (genetic markers)</td></tr><tr><td rowspan="2"></td><td>IgA anti-tissue transglutaminase antibodies (IgA anti-tTG, IgG anti-tTG antibodies)</td><td>Mucous membrane thickness</td><td r... | <table><tr><td rowspan="2"></td><td>Anti-deamidated gliadin peptide (IgA anti-DGP, IgG anti-DGP)</td><td>Crypt depth</td><td rowspan="2">HLA-typing</td></tr><tr><td></td><td>Crypt-villus ratio</td></tr><tr><td>Limitations</td><td>Specificity and sensitivity of test method; the active period of the disease; long-term gl... |
e8ae8a8609c2fd0bef5d687ba3f7d1162ef5654894e6234b6eee6e03dba06adc.png | complex | <table><tr><td></td><td colspan="2">Caf1</td><td colspan="2">Ccr4</td></tr><tr><td></td><td>Gene</td><td>Synonyms</td><td>Gene</td><td>Synonyms</td></tr><tr><td><i>Saccharomyces cerevisiae</i></td><td>POP2</td><td>CAF1</td><td>CCR4</td><td>FUN27, NUT21</td></tr><tr><td><i>Schizosaccharomyces pombe</i></td><td>caf1</td>... | <table><tr><td></td><td>Caf1</td></tr><tr><td></td><td>Gene</td></tr><tr><td>Saccharomyces cerevisiae</td><td>POP2</td></tr><tr><td>Schizosaccharomyces pombe</td><td>caf1</td></tr><tr><td>Caenorhabditis elegans</td><td>CCF-1</td></tr><tr><td>Drosophila melanogaster</td><td>Pop2</td></tr><tr><td>Xenopus laevis</td><td>C... | <table><tr><td>Caf1</td><td colspan="2">Ccr4</td></tr><tr><td>Synonyms</td><td>Gene</td><td>Synonyms</td></tr><tr><td>CAF1</td><td>CCR4</td><td>FUN27, NUT21</td></tr><tr><td>pop2</td><td>CCR4</td><td></td></tr><tr><td></td><td>CCR-4</td><td></td></tr><tr><td>CAF1</td><td>Twin</td><td>CCR4</td></tr><tr><td>caf1, caf-1</... |
458a0d1e2c182c150e73e3dc325b974122fcabf057001afc60302903abf0e302.png | complex | <table><tr><td colspan="2">Variables<sup>a</sup></td><td>High risk (n = 1170)</td><td>Not high risk (n = 563)</td><td><i>P</i> value<sup>*</sup></td></tr><tr><td colspan="2">Gender</td><td></td><td></td><td></td></tr><tr><td></td><td>Male</td><td>463 (39.6)</td><td>372 (66.1)</td><td><0.001</td></tr><tr><td></td><td... | <table><tr><td colspan="2">Variablesa</td><td>High risk (n = 1170)</td><td>Not high risk (n = 563)</td><td>P value*</td></tr><tr><td colspan="2">Gender</td><td></td><td></td><td></td></tr><tr><td></td><td>Male</td><td>463 (39.6)</td><td>372 (66.1)</td><td><0.001</td></tr><tr><td></td><td>Female</td><td>707 (60.4)</td><... | <table><tr><td></td><td>Lower-middle income (906–3595)</td><td>818 (69.9)</td><td>410 (72.8)</td><td></td></tr><tr><td></td><td>Upper-middle income (3596–11115)</td><td>7 (0.6)</td><td>3 (0.5)</td><td></td></tr><tr><td colspan="2">Employment status</td><td></td><td></td><td></td></tr><tr><td></td><td>Unemployed/ sacked... |
cb5dbc3068f2ffdff9330bb1de87d0678e2e27f8a5cb194e7f1effdbfd628713.png | simple | <table><tr><td>Factors</td><td>Have you ever attended VCT (N (%))</td><td></td><td></td><td></td></tr><tr><td></td><td>Yes</td><td>No</td><td>χ<sup>2</sup></td><td>p-value</td></tr><tr><td>Religion</td><td></td><td></td><td></td><td></td></tr><tr><td>Protestant</td><td>36(29.3)</td><td>87(70.7)</td><td>5.6</td><td... | <table><tr><td>Factors</td><td>Have you ever attended VCT (N (%))</td><td></td><td></td><td></td></tr><tr><td></td><td>Yes</td><td>No</td><td>χ2</td><td>p-value</td></tr><tr><td>Religion</td><td></td><td></td><td></td><td></td></tr><tr><td>Protestant</td><td>36(29.3)</td><td>87(70.7)</td><td>5.6</td><td>0.13</td></tr><... | <table><tr><td>Physiotherapist</td><td>14(13.1)</td><td>21(10.4)</td><td></td><td></td></tr><tr><td>Others</td><td>25(23.4)</td><td>56(27.7)</td><td></td><td></td></tr><tr><td>Age group</td><td></td><td></td><td></td><td></td></tr><tr><td>18–21</td><td>16(15)</td><td>31(15.3)</td><td>3.9</td><td>0.14</td></tr><tr><td>2... |
80eb5ade60a72ce9cae6eeb5e47f5e475f0e02fbdb0447f94bea58f3e9661bb9.png | simple | <table><tr><td></td><td>Total</td></tr><tr><td>No. of patients</td><td>394</td></tr><tr><td>Age (years)</td><td></td></tr><tr><td> Mean ± SD</td><td>57.0 ± 12.8</td></tr><tr><td> Range</td><td>28-94</td></tr><tr><td>Tumor size (cm)</td><td></td></tr><tr><td> ≤2.0</td><td>197 (50.0%)</td></tr><tr><td> 2.... | <table><tr><td></td><td>Total</td></tr><tr><td>No. of patients</td><td>394</td></tr><tr><td>Age (years)</td><td></td></tr><tr><td>Mean ± SD</td><td>57.0 ± 12.8</td></tr><tr><td>Range</td><td>28-94</td></tr></table> | <table><tr><td>Tumor size (cm)</td><td></td></tr><tr><td>≤2.0</td><td>197 (50.0%)</td></tr><tr><td>2.1-5.0</td><td>183 (46.5%)</td></tr><tr><td>>5.0</td><td>12 (3.1%)</td></tr><tr><td>Unknown</td><td>2 (0.4%)</td></tr><tr><td>No. of positive lymph nodes</td><td></td></tr><tr><td>0</td><td>207 (52.5%)</td></tr><tr><td>1... |
4eb6feafbc39ac3cbf6c5960b3039c83fd5ad045ff2e44a0c784e3ce682fe224.png | simple | <table><tr><td>Patient number</td><td>Patient age</td><td>Early or late infection</td><td>Procedure</td><td>Time after first washout that NPWT was applied</td><td>Duration of NPWT</td><td>Number of NPWT changes</td><td>Long-term outcome</td></tr><tr><td>1</td><td>17 years</td><td>Late</td><td>Corrective surgery for sev... | <table><tr><td>Patient number</td><td>Patient age</td><td>Early or late infection</td></tr><tr><td>1</td><td>17 years</td><td>Late</td></tr><tr><td>2</td><td>46 years</td><td>Early</td></tr><tr><td>3</td><td>43 years</td><td>Early</td></tr><tr><td>4</td><td>41 years</td><td>Early</td></tr><tr><td>5</td><td>72 years</td... | <table><tr><td>Procedure</td><td>Time after first washout that NPWT was applied</td><td>Duration of NPWT</td><td>Number of NPWT changes</td><td>Long-term outcome</td></tr><tr><td>Corrective surgery for severe scoliosis</td><td>0 days</td><td>21 days</td><td>3</td><td>Metalwork retained, no infection</td></tr><tr><td>In... |
37ba41baf7e871f5ac5d3ce2ddf958a739162e230c352122569fe846ee6ad9c5.png | simple | <table><tr><td>MAA Category</td><td>Commercial Agreement</td><td>Payment for Performance Agreement</td><td>Coverage with Evidence Development</td></tr><tr><td>Contract type</td><td>• Discount-based contract</td><td>• Permanent risk-shifting agreement (outcomes guarantee/insurance) applied on a per-patient b... | <table><tr><td>MAA Category</td><td>Commercial Agreement</td><td>Payment for Performance Agreement</td><td>Coverage with Evidence Development</td></tr><tr><td>Contract type</td><td>• Discount-based contract</td><td>• Permanent risk-shifting agreement (outcomes guarantee/insurance) applied on a per-patient basis</td><td... | <table><tr><td>MAA Category</td><td>Commercial Agreement</td><td>Payment for Performance Agreement</td><td>Coverage with Evidence Development</td></tr><tr><td>Timeframe of the MAA</td><td>• Permanent/not linked to final decision-making</td><td>• Permanent/not linked to final decision-making based on new robust evidence... |
79fc1464ddbea81683cf8c1a44051e6ea46857236ad6aad00fc47497d0846e9a.png | simple | <table><tr><td></td><td>All patients</td><td>Cases</td><td>Control</td></tr><tr><td>Samples</td><td>10,324</td><td>6,564</td><td>5,072<sup>b</sup></td></tr><tr><td>Identified CNVs</td><td>14,226<sup>a</sup></td><td>9,186</td><td>495,916</td></tr><tr><td>Type of CNVs:</td><td></td><td></td><td></td></tr><tr><td>Loss</td... | <table><tr><td></td><td>All patients</td><td>Cases</td></tr><tr><td>Samples</td><td>10,324</td><td>6,564</td></tr><tr><td>Identified CNVs</td><td>14,226a</td><td>9,186</td></tr><tr><td>Type of CNVs:</td><td></td><td></td></tr><tr><td>Loss</td><td>7,554</td><td>5,101</td></tr><tr><td>Gain</td><td>6,672</td><td>4,085</td... | <table><tr><td>Control</td></tr><tr><td>5,072b</td></tr><tr><td>495,916</td></tr><tr><td></td></tr><tr><td>343,489</td></tr><tr><td>152,427</td></tr><tr><td>31</td></tr><tr><td></td></tr><tr><td></td></tr><tr><td></td></tr><tr><td></td></tr><tr><td></td></tr></table> |
04929abbdddd8373905cf506ae23ad50e313e9c673116f652d477ad9c81a9e98.png | complex | <table><tr><td rowspan="2"> </td><td colspan="3">Flexion</td><td colspan="3">Extension</td></tr><tr><td>Pre-operation</td><td>13 months after the operation</td><td>18 months after the operation</td><td>Pre-operation</td><td>13 months after the operation</td><td>18 months after the operation</td></tr><tr><td>Left hip</t... | <table><tr><td rowspan="2"></td><td>Flexion</td></tr><tr><td>Pre-operation</td></tr><tr><td>Left hip</td><td>0°-25°</td></tr><tr><td>Right hip</td><td>0°-15°</td></tr><tr><td>Left knee</td><td>0°-15°</td></tr><tr><td>Right knee</td><td>0°-10°</td></tr></table> | <table><tr><td colspan="2">Flexion</td><td colspan="3">Extension</td></tr><tr><td>13 months after the operation</td><td>18 months after the operation</td><td>Pre-operation</td><td>13 months after the operation</td><td>18 months after the operation</td></tr><tr><td>0°-85°</td><td>0°-110°</td><td rowspan="4">Flexion defo... |
f5285e92dbbfa8a398fba89abd500ccff30b8003ad7f28896855d878bbd20134.png | simple | <table><tr><td>Trait</td><td>Description (ability assessed)</td><td>CLDRC-RD (564)</td><td>UK-RD (958)</td><td>SLIC (498)</td><td>CLDRC-ADHD (163)</td></tr><tr><td>WRead</td><td>Reading real words</td><td>x (0.918)</td><td>x (0.918)</td><td>x (0.902)</td><td>x (0.871)</td></tr><tr><td>WSpell</td><td>Spelling real words... | <table><tr><td>Trait</td><td>Description (ability assessed)</td><td>CLDRC-RD (564)</td><td>UK-RD (958)</td><td>SLIC (498)</td><td>CLDRC-ADHD (163)</td></tr><tr><td>WRead</td><td>Reading real words</td><td>x (0.918)</td><td>x (0.918)</td><td>x (0.902)</td><td>x (0.871)</td></tr><tr><td>WSpell</td><td>Spelling real words... | <table><tr><td>Trait</td><td>Description (ability assessed)</td><td>CLDRC-RD (564)</td><td>UK-RD (958)</td><td>SLIC (498)</td><td>CLDRC-ADHD (163)</td></tr><tr><td>RLS</td><td>Listening and auditory comprehension (receptive domain of language)</td><td></td><td></td><td>x (0.837)</td><td></td></tr><tr><td>VIQ</td><td>Ve... |
227265bbd9a416bd00c19e002339c49f7310e830a12c705f56631f9c3e32bf66.png | simple | <table><tr><td> </td><td><i>T-cell development</i></td><td><i>Naive T-cell homeostasis</i></td><td><i>T-cell activation</i></td><td><i>T-cell differentiation</i></td><td><i>T-cell memory</i></td><td><i>References</i></td></tr><tr><td><i>Slc7a5</i><sup>–/–</sup> mice</td><td>No</td><td>No</td><td>T-cell acti... | <table><tr><td></td><td>T-cell development</td><td>Naive T-cell homeostasis</td><td>T-cell activation</td><td>T-cell differentiation</td><td>T-cell memory</td><td>References</td></tr></table> | <table><tr><td>Slc7a5–/– mice</td><td>No</td><td>No</td><td>T-cell activation↓</td><td>Th1 and Th17 cells↓</td><td>Not available</td><td>11</td></tr><tr><td>Slc1a5–/– mice</td><td>No</td><td>(1) For young micea: No (2) For older miceb: CD4+ T cells↓CD44loCD62Lhi CD4+ T cells↑</td><td>Activation of mTORC1 in T cellsc↓</... |
3229bac2195d4ebc7500856bdbe81d3d66d4e9f733e5c938b3b037e367af6436.png | simple | <table><tr><td>Term</td><td>Number of medications</td><td>Number of studies</td><td>References</td></tr><tr><td>Polypharmacy</td><td>≥ 2 for > 240 days (long term)</td><td>1</td><td>[101]</td></tr><tr><td></td><td>≥ 5 medications in the same month</td><td>1</td><td>[103]</td></tr><tr><td></td><td>> 5 ... | <table><tr><td>Term</td><td>Number of medications</td><td>Number of studies</td></tr><tr><td>Polypharmacy</td><td>≥ 2 for > 240 days (long term)</td><td>1</td></tr><tr><td></td><td>≥ 5 medications in the same month</td><td>1</td></tr><tr><td></td><td>> 5 medications for ≥ 90 days</td><td>1</td></tr><tr><td></td><td>≥ 5... | <table><tr><td>References</td></tr><tr><td>[101]</td></tr><tr><td>[103]</td></tr><tr><td>[104]</td></tr><tr><td>[105]</td></tr><tr><td>[106]</td></tr><tr><td>[107]</td></tr><tr><td>[108]</td></tr><tr><td>[109]</td></tr><tr><td>[110]</td></tr><tr><td>[107]</td></tr><tr><td>[108]</td></tr><tr><td>[105]</td></tr><tr><td>[... |
931d390c5553904bf414c05b05cb9ba4580a527387764494ffa7bc12da06ddf2.png | simple | <table><tr><td>Category</td><td>Treatment group (<i>n</i> = 16)</td><td>Control group (<i>n</i> = 12)</td><td><i>P</i> value</td></tr><tr><td>Age (months)</td><td>136 (93–216)</td><td>140 (96–176)</td><td>0.82</td></tr><tr><td>Weight (kgs)</td><td>7.70 (1.44–27.82)</td><td>4.75 (1.63–29.09)</td>... | <table><tr><td>Category</td><td>Treatment group (n = 16)</td><td>Control group (n = 12)</td><td>P value</td></tr><tr><td>Age (months)</td><td>136 (93–216)</td><td>140 (96–176)</td><td>0.82</td></tr><tr><td>Weight (kgs)</td><td>7.70 (1.44–27.82)</td><td>4.75 (1.63–29.09)</td><td>0.39</td></tr><tr><td>Coughing</td><td>8/... | <table><tr><td>Abdominal Distension</td><td>5/16</td><td>0/12</td><td>0.18</td></tr><tr><td>Respiratory Distress</td><td>13/16</td><td>10/12</td><td>0.73</td></tr><tr><td>Lethargy</td><td>8/16</td><td>5/12</td><td>0.67</td></tr><tr><td>Syncope</td><td>2/16</td><td>4/12</td><td>0.64</td></tr><tr><td>Exercise Intolerance... |
0914f4a15df0cd49d7a9d9e73dfe9af02af7dcece8b853e921daf5e2215ab7e9.png | simple | <table><tr><td>Water Microbe</td><td>Amplified NuclearRibosomal Regions</td><td>Primer Sets (from 5' to 3')</td><td>PCR Program</td></tr><tr><td>Bacteria [19,20]</td><td>16S rRNA V4-V5 region</td><td>515F: GTGCCAGCMGCCGCGGTAA907R: CCGTCAATTCCTTTGAGTTT</td><td>95°C for 2 min, 30 cycles of 95°C for 30 s, 55... | <table><tr><td>Water Microbe</td><td>Amplified NuclearRibosomal Regions</td><td>Primer Sets (from 5' to 3')</td><td>PCR Program</td></tr><tr><td>Bacter</td><td>16S rRNA V4-V5 reg</td><td>51</td><td>95°C for 2</td></tr></table> | <table><tr><td>ia [19,20]</td><td>ion</td><td>5F: GTGCCAGCMGCCGCGGTAA907R: CCGTCAATTCCTTTGAGTTT</td><td> min, 30 cycles of 95°C for 30 s, 55°C for 30 s, 72°C for 30 s, with a final extension at 72°C for 5 min</td></tr><tr><td>Fungi [21]</td><td>Internal transcribedspacer-1 (ITS1) region</td><td>1737F:GGAAGTAAAAGTCGTAAC... |
c28f769c56f37a4ddbe0ea5afe53e41e8ec11d04a03b526266290c8d23b37f65.png | simple | <table><tr><td>whale</td><td>age/sex</td><td>year</td><td>tag duration (days)</td><td>min. latitude (° S)</td><td>max. SST (°C)</td></tr><tr><td>1</td><td>adult/female</td><td>2009</td><td>08 Jan–16 Jan (9)</td><td>64</td><td>2.3</td></tr><tr><td>2</td><td>adult/female</td><td>2009</td><td>14 Jan–... | <table><tr><td>whale</td><td>age/sex</td><td>year</td><td>tag duration (days)</td><td>min. latitude (° S)</td><td>max. SST (°C)</td></tr><tr><td>1</td><td>adult/female</td><td>2009</td><td>08 Jan–16 Jan (9)</td><td>64</td><td>2.3</td></tr><tr><td>2</td><td>adult/female</td><td>2009</td><td>14 Jan–27 Jan (14)</td><td>67... | <table><tr><td>whale</td><td>age/sex</td><td>year</td><td>tag duration (days)</td><td>min. latitude (° S)</td><td>max. SST (°C)</td></tr><tr><td>8</td><td>adult/male</td><td>2011</td><td>13 Jan–31 Jan (19)</td><td>67</td><td>1.8</td></tr><tr><td>9</td><td>adult/female</td><td>2011</td><td>13 Jan–25 Feb (44)</td><td>37<... |
7465703eaf50cec176937fec5ed5c1b31501568dc6a463cdb15aea6fca3e6239.png | simple | <table><tr><td>Age (yrs)</td><td>Weight (kg)</td><td>Gender</td><td>Ethnicity</td><td>Indication</td><td>Target INR</td><td>Drug Interaction(s)</td><td>Therapeutic warfarin dose (mg/d)</td><td>Reference</td></tr><tr><td>69</td><td>79.8</td><td>Female </td><td>Japanese</td><td>AFib</td><td>1.5–20</td><td>NR</td><t... | <table><tr><td>Age (yrs)</td><td>Weight (kg)</td><td>Gender</td><td>Ethnicity</td><td>Indication</td><td>Target INR</td><td>Drug Interaction(s)</td><td>Therapeutic warfarin dose (mg/d)</td><td>Reference</td></tr><tr><td>69</td><td>79.8</td><td>Female</td><td>Japanese</td><td>AFib</td><td>1.5–20</td><td>NR</td><td>0.5</... | <table><tr><td>Age (yrs)</td><td>Weight (kg)</td><td>Gender</td><td>Ethnicity</td><td>Indication</td><td>Target INR</td><td>Drug Interaction(s)</td><td>Therapeutic warfarin dose (mg/d)</td><td>Reference</td></tr><tr><td>50</td><td>88</td><td>Male</td><td>Chinese</td><td>AFib</td><td>2.0–3.0</td><td>NR</td><td>1.25</td>... |
60a84dd3c0f72497af355c2146c73492341c2c66a93d5281ace6bcce69af006e.png | complex | <table><tr><td></td><td>N</td><td>%</td></tr><tr><td>Clozapine</td><td>9</td><td>39</td></tr><tr><td>Other antipsychotics</td><td>14</td><td>61</td></tr><tr><td> Traditional antipsychotics</td><td>6</td><td>26</td></tr><tr><td> Atypical antipsychotics</td><td>8</td><td>35</td></tr><tr><td>Mood stabilizers</td><td>5</td... | <table><tr><td></td><td>N</td></tr><tr><td>Clozapine</td><td>9</td></tr><tr><td>Other antipsychotics</td><td>14</td></tr><tr><td>Traditional antipsychotics</td><td>6</td></tr><tr><td>Atypical antipsychotics</td><td>8</td></tr><tr><td>Mood stabilizers</td><td>5</td></tr><tr><td>Clozapine dose</td><td>481 ± 218 mg (range... | <table><tr><td>%</td></tr><tr><td>39</td></tr><tr><td>61</td></tr><tr><td>26</td></tr><tr><td>35</td></tr><tr><td>22</td></tr><tr><td>481 ± 218 mg (range 300 - 900)</td></tr><tr><td>1671 ± 1164 μmol/l (range 326 - 3333)</td></tr></table> |
c1dc7e27f960418fe1009d2cdceb319ed569e5dbc952fcf3220bb79c3873a60c.png | complex | <table><tr><td rowspan="2">Barrier</td><td colspan="2">1<sup>st</sup> Barrier</td><td colspan="2">2<sup>nd</sup> Barrier</td><td colspan="2">3<sup>rd</sup> Barrier</td><td>Total</td></tr><tr><td>Freq</td><td>%</td><td>Freq</td><td>%</td><td>Freq</td><td>%</td><td><i>N</i></td></tr><tr><td>Delay before care is received<... | <table><tr><td rowspan="2">Barrier</td><td colspan="2">1st Barrier</td></tr><tr><td>Freq</td><td>%</td></tr><tr><td>Delay before care is received</td><td>59</td><td>10.9</td></tr><tr><td>Long distance to treatment centres</td><td>6</td><td>1.1</td></tr><tr><td>Financial challenges</td><td>68</td><td>12.6</td></tr><tr><... | <table><tr><td colspan="2">2nd Barrier</td><td colspan="2">3rd Barrier</td><td>Total</td></tr><tr><td>Freq</td><td>%</td><td>Freq</td><td>%</td><td>N</td></tr><tr><td>35</td><td>6.5</td><td>9</td><td>1.7</td><td>103</td></tr><tr><td>24</td><td>4.5</td><td>11</td><td>2</td><td>41</td></tr><tr><td>24</td><td>4.4</td><td>... |
beef9b9ee451acf4bfe5fa1c66f7cc9b8622d6640a15b29b13dc6d6b941de55e.png | simple | <table><tr><td>Variable</td><td>Unadjusted</td><td>Adjusted for CRP/AGP <sup>2</sup></td></tr><tr><td>Participants (<i>n</i>) <sup>3</sup></td><td>770</td><td>770</td></tr><tr><td>Hb concentration, g/dL <sup>4</sup></td><td>9.6 (9.5,9.8)</td><td>-</td></tr><tr><td>Anemia, Hb < 10.5 g/dL (2nd trimester) or 11.0 g/dL ... | <table><tr><td>Variable</td><td>Unadjusted</td><td>Adjusted for CRP/AGP 2</td></tr><tr><td>Participants (n) 3</td><td>770</td><td>770</td></tr><tr><td>Hb concentration, g/dL 4</td><td>9.6 (9.5,9.8)</td><td>-</td></tr><tr><td>Anemia, Hb < 10.5 g/dL (2nd trimester) or 11.0 g/dL (1st, 3rd trimester)</td><td>601 (79.0)</td... | <table><tr><td>CRP, mg/L</td><td>2.2 (2.0, 2.4)</td><td>-</td></tr><tr><td>CRP > 5 mg/L</td><td>189 (24.6)</td><td>-</td></tr><tr><td>Malaria antigenemia (elevated HRP2) 8</td><td>97 (12.6)</td><td>-</td></tr></table> |
e347910cf9ef5315c661266d76a6e15caba4e9870a7ec300776fb401bec454fe.png | complex | <table><tr><td rowspan="2">Country</td><td rowspan="2">Year of data collection</td><td colspan="6">Male</td><td colspan="8">Female</td></tr><tr><td>lung</td><td>stomach</td><td>large bowel</td><td>prostate</td><td>kidney</td><td>urinary bladder</td><td>lung</td><td>stomach</td><td>large bowel</td><td>breast</td><td>cer... | <table><tr><td rowspan="2">Country</td><td rowspan="2">Year of data collection</td><td colspan="6">Male</td><td colspan="8">Female</td></tr><tr><td>lung</td><td>stomach</td><td>large bowel</td><td>prostate</td><td>kidney</td><td>urinary bladder</td><td>lung</td><td>stomach</td><td>large bowel</td><td>breast</td><td>cer... | <table><tr><td>Slovakia</td><td>2004</td><td>55.8</td><td>16.1</td><td>55.5</td><td>33.9</td><td>14.9</td><td>15.9</td><td>10.4</td><td>7.0</td><td>27.7</td><td>49.7</td><td>15.2</td><td>11.5</td><td>6.6</td><td>4.1</td></tr></table> |
f4d2eeab02360850a1151f154ab38444f0a7524a58f448dbda8fa95e4b325e95.png | complex | <table><tr><td>Parameters</td><td>Lead (Pb)</td><td>Cadmium (Cd)</td><td>Zinc (Zn)</td><td>Iron (Fe)</td><td>References</td></tr><tr><td>Water concentration (ppm)</td><td>0.33 ± 0.03</td><td>0.02 ± 0.00*</td><td>0.01 ± 0.00**</td><td>2.61 ± 0.07**</td><td>This study</td></tr><tr><td>Liver concentrat... | <table><tr><td>Parameters</td><td>Lead (Pb)</td><td>Cadmium (Cd)</td><td>Zinc (Zn)</td><td>Iron (Fe)</td><td>References</td></tr><tr><td>Water concentration (ppm)</td><td>0.33 ± 0.03</td><td>0.02 ± 0.00*</td><td>0.01 ± 0.00**</td><td>2.61 ± 0.07**</td><td>This study</td></tr><tr><td>Liver concentration (ppm)</td><td>0.... | <table><tr><td>Bioaccumulation factor</td><td>1.06</td><td>2.00</td><td>217.00</td><td>4.46</td><td>This study</td></tr><tr><td rowspan="2">Maximum acceptable water limit (ppm)</td><td>0.01</td><td>0.003</td><td>3.00</td><td>0.30</td><td>NIS (2007)</td></tr><tr><td>0.01</td><td>0.01</td><td>5.00</td><td>0.30</td><td>WH... |
0e559518f626ffc1660d1446264f3fb46fa135e211bc85f9dfaa73a63e8e4c50.png | complex | <table><tr><td>Factor</td><td colspan="2">Prokaryotic community (<i>P</i>/R)</td><td></td><td colspan="2">Fungal community (<i>P</i>/R)</td></tr><tr><td></td><td>Chao1 (Richness)</td><td>Shannon</td><td></td><td>Chao1 (Richness)</td><td>Shannon</td></tr><tr><td>Na</td><td>0.489/-0.006</td><td>0.592/-0.033</td><td></td>... | <table><tr><td>Factor</td></tr><tr><td></td></tr><tr><td>Na</td></tr><tr><td>S</td></tr><tr><td>P</td></tr><tr><td>Ca</td></tr><tr><td>K</td></tr><tr><td>Mg</td></tr><tr><td>Fe</td></tr><tr><td>Al</td></tr><tr><td>As</td></tr><tr><td>B</td></tr><tr><td>Ba</td></tr><tr><td>Cd</td></tr><tr><td>Co</td></tr><tr><td>Cr</td>... | <table><tr><td colspan="2">Prokaryotic community (P/R)</td><td></td><td colspan="2">Fungal community (P/R)</td></tr><tr><td>Chao1 (Richness)</td><td>Shannon</td><td></td><td>Chao1 (Richness)</td><td>Shannon</td></tr><tr><td>0.489/-0.006</td><td>0.592/-0.033</td><td></td><td>0.280/0.042</td><td>0.067/0.156</td></tr><tr>... |
7bdc4d8018002a3f3caac8535d9e206c68b6e8566d828037c6a37d3ef2e80424.png | simple | <table><tr><td>Fatty acid</td><td>Overall <i>N</i> = 3196</td><td>Male <i>N</i> = 1434</td><td>Female <i>N</i> = 1762</td><td><i>P</i> value*</td></tr><tr><td>Myristic, C14:0</td><td>0.31 (0.08)</td><td>0.29 (0.07)</td><td>0.32 (0.09)</td><td><0.0001</td></tr><tr><td>Palmitic, C16:0</td><td>21.29 (1.24)</td><td>21.2... | <table><tr><td>Fatty acid</td><td>Overall N = 3196</td><td>Male N = 1434</td><td>Female N = 1762</td><td>P value*</td></tr><tr><td>Myristic, C14:0</td><td>0.31 (0.08)</td><td>0.29 (0.07)</td><td>0.32 (0.09)</td><td><0.0001</td></tr><tr><td>Palmitic, C16:0</td><td>21.29 (1.24)</td><td>21.24 (1.21)</td><td>21.34 (1.26)</... | <table><tr><td>Oleic, C18:1</td><td>13.88 (1.06)</td><td>13.90 (1.06)</td><td>13.85 (1.06)</td><td>0.23</td></tr><tr><td>Eicosenoic, C20:1</td><td>0.27 (0.11)</td><td>0.28 (0.12)</td><td>0.27 (0.10)</td><td><0.0001</td></tr><tr><td>Nervonic, C24:1</td><td>0.45 (0.15)</td><td>0.46 (0.15)</td><td>0.43 (0.15)</td><td><0.0... |
9997778607d72ceb7ab82835009ffbac248ce2b073822896418a4e3db5eeb659.png | simple | <table><tr><td>Factor</td><td>Effect on efficiency</td><td>Implications</td></tr><tr><td>Decreased morale</td><td>Decrease</td><td>Increase staff support and supervision, plan for retention, access to ART</td></tr><tr><td>Increased experience</td><td>Increase</td><td>Plan to increase retention to keep experienced staff... | <table><tr><td>Factor</td><td>Effect on efficiency</td><td>Implications</td></tr><tr><td>Decreased morale</td><td>Decrease</td><td>Increase staff support and supervision, plan for retention, access to ART</td></tr><tr><td>Increased experi</td><td>In</td><td>Plan to increase retention to keep experience</td></tr></table... | <table><tr><td>ence</td><td>crease</td><td>d staff</td></tr><tr><td>Increased training</td><td>Increase long term (short-term training time may decrease efficiency)</td><td>Plan for quality training on-hire (practical and didactic), continuing education, work to integrate into preclinical education in health services</... |
d892e0c31b84afedcd8e2e13edcd1abf97761462d9a7793085acd751754d8f47.png | complex | <table><tr><td></td><td colspan="3">Number</td></tr><tr><td></td><td>Round 1</td><td>Round 2</td><td>Round 3</td></tr><tr><td>Participant response rate</td><td>34/49 (70%)</td><td>33/34 (97%)</td><td>32/33 (97%)</td></tr><tr><td>Gender</td><td></td><td></td><td></td></tr><tr><td> Male</td><td>8 (23.5%)</td><td>8 (24.2%... | <table><tr><td></td><td colspan="3">Number</td></tr><tr><td></td><td>Round 1</td><td>Round 2</td><td>Round 3</td></tr><tr><td>Participant response rate</td><td>34/49 (70%)</td><td>33/34 (97%)</td><td>32/33 (97%)</td></tr><tr><td>Gender</td><td></td><td></td><td></td></tr><tr><td>Male</td><td>8 (23.5%)</td><td>8 (24.2%)... | <table><tr><td>Work experience (years)</td><td></td><td></td><td></td></tr><tr><td>5–15</td><td>25 (73.5%)</td><td>24 (72.7%)</td><td>23 (71.9%)</td></tr><tr><td>16–25</td><td>8 (23.5%)</td><td>8 (24.2%)</td><td>8 (25%)</td></tr><tr><td>26–30</td><td>1 (2.9%)</td><td>1 (3.03%)</td><td>1 (3.1%)</td></tr><tr><td>Educatio... |
4243adae04103dba490259a59cb47fe757faf9ec1ec63ec55c46267bafa30055.png | simple | <table><tr><td>Compounds</td><td><i>E</i><sub>e</sub>/au</td><td>(Δ<i>E</i><sub>b</sub>) kcal/mol</td><td><i>E</i><sub>BSSE</sub></td><td>(Δ<i>E</i><sub>b-bsse</sub>) kcal/mol</td><td><i>E</i><sub>c</sub></td><td>(Δ<i>E</i><sub>cb</sub>) kcal/mol</td><td><i>H</i>\au</td><td>Δ<i>H</i> kcal/mol</td></... | <table><tr><td>Compounds</td><td>Ee/au</td><td>(ΔEb) kcal/mol</td><td>EBSSE</td><td>(ΔEb-bsse) kcal/mol</td><td>Ec</td><td>(ΔEcb) kcal/mol</td><td>H\au</td><td>ΔH kcal/mol</td></tr><tr><td>L-Dopa</td><td>−705.45367</td><td></td><td></td><td></td><td>−705.25677</td><td></td><td>−705.24186</td><td></td></tr><tr><td>LD-W1... | <table><tr><td>LD-W2</td><td>−781.91946</td><td>−4.598</td><td>−781.91112</td><td>−0.63377</td><td>−781.69836</td><td>−2.783</td><td>−781.68007</td><td>−3.026</td></tr><tr><td>LD-W3</td><td>−781.92633</td><td>−8.905</td><td>−781.90779</td><td>−2.72335</td><td>−781.70373</td><td>−5.939</td><td>−781.68652</td><td>−7.073<... |
a5fff2874247418b90506c571ede32e808c2a1f4e3984cacfe224f7c0e000f79.png | simple | <table><tr><td></td><td>A/CPA patients</td><td>Pure APA patients</td><td><i>P</i> value</td></tr><tr><td>Number of cases</td><td>22</td><td>392</td><td></td></tr><tr><td>Age (years)</td><td>40.32 ± 6.37</td><td>38.37 ± 7.76</td><td>0.1255</td></tr><tr><td>Age range (years)</td><td>26–51</td><td>19–... | <table><tr><td></td><td>A/CPA patients</td><td>Pure APA patients</td><td>P value</td></tr><tr><td>Number of cases</td><td>22</td><td>392</td><td></td></tr><tr><td>Age (years)</td><td>40.32 ± 6.37</td><td>38.37 ± 7.76</td><td>0.1255</td></tr><tr><td>Age range (years)</td><td>26–51</td><td>19–58</td><td></td></tr><tr><td... | <table><tr><td>Metabolic syndrome, n (%)</td><td>8 (36.36%)</td><td>72 (18.37%)</td><td>0.0375∗</td></tr><tr><td>Cortisol excess screening, n (%)‡</td><td>22 (100%)</td><td>392 (100%)</td><td>—</td></tr><tr><td>Confirmation test performed, n (%)§</td><td>22 (100%)</td><td>264 (67.35%)</td><td>—</td></tr><tr><td>Aldoste... |
929778d428d4c570632bbd69c9e1e989db0d6bc286344344e305be5b1eab21f6.png | complex | <table><tr><td rowspan="2">Error type and antimicrobial</td><td rowspan="2">Organism</td><td rowspan="2">No. of errors</td><td colspan="2">MIC<sup><i>a</i></sup></td><td colspan="2">AST result<sup><i>b</i></sup></td><td colspan="2">Breakpoint<sup><i>a</i></sup></td><td colspan="2">Reportable range<sup><i>a</i></sup></t... | <table><tr><td rowspan="2">Error type and antimicrobial</td><td rowspan="2">Organism</td><td rowspan="2">No. of errors</td><td colspan="2">MICa</td><td colspan="2">AST resultb</td><td colspan="2">Breakpointa</td><td colspan="2">Reportable rangea</td></tr><tr><td>AXDX</td><td>REF</td><td>AXDX</td><td>REF</td><td>S</td><... | <table><tr><td>n</td><td>lococcus aureus</td><td></td><td>≥16</td><td></td><td>R</td><td>S</td><td></td><td>8</td><td>125</td><td></td></tr><tr><td rowspan="2">Cefoxitin (MRSA/MRS)</td><td>Staphylococcus epidermidis</td><td>1</td><td>N/A</td><td>N/A</td><td>POS</td><td>NEG</td><td>4</td><td>8</td><td>4</td><td>8</td></... |
091d042282da17f2ce87a05ebd1c805ce7ad00a23a143417ea9c2b7f7eb42a77.png | complex | <table><tr><td></td><td>Target population (<i>n</i> = 5)</td><td>Key stakeholders (<i>n</i> = 5)</td></tr><tr><td>Gender</td><td>Male (4)</td><td>Male (3)</td></tr><tr><td>Age</td><td>21–34 years 
(mean: 26 years)</td><td>23–38 years 
(mean: 29 years)</td></tr><tr><td rowspan="4">Educational sta... | <table><tr><td></td><td>Target population (n = 5)</td></tr><tr><td>Gender</td><td>Male (4)</td></tr><tr><td>Age</td><td>21–34 years
(mean: 26 years)</td></tr><tr><td rowspan="4">Educational status</td><td>Primary (1)</td></tr><tr><td>Secondary (2)</td></tr><tr><td>High-school (1)</td></tr><tr><td>Bachelors (1)</td></t... | <table><tr><td>Key stakeholders (n = 5)</td></tr><tr><td>Male (3)</td></tr><tr><td>23–38 years
(mean: 29 years)</td></tr><tr><td>High-school (2)</td></tr><tr><td>Bachelors (2)</td></tr><tr><td>Masters (1)</td></tr><tr><td></td></tr><tr><td rowspan="4">n/a</td></tr><tr></tr><tr></tr><tr></tr><tr><td>Coordinator (1)</td... |
9671248b31598833e9ce5af8c9810a2d92ae27260ba5db866e0262906c65d357.png | simple | <table><tr><td> </td><td>No. (%)</td></tr><tr><td>State of health</td><td> </td></tr><tr><td>Good</td><td>349 (37.0)</td></tr><tr><td>Poor</td><td>595 (63.0)</td></tr><tr><td>Emotional status</td><td> </td></tr><tr><td>Blank</td><td>144 (15.3)</td></tr><tr><td>Unhappy (ever)</td><td>99 (10.5)</td></tr><tr><td>Ordinary<... | <table><tr><td></td><td>No. (%)</td></tr><tr><td>State of health</td><td></td></tr><tr><td>Good</td><td>349 (37.0)</td></tr><tr><td>Poor</td><td>595 (63.0)</td></tr><tr><td>Emotional status</td><td></td></tr><tr><td>Blank</td><td>144 (15.3)</td></tr><tr><td>Unhappy (ever)</td><td>99 (10.5)</td></tr></table> | <table><tr><td></td><td>No. (%)</td></tr><tr><td>Ordinary</td><td>343 (36.3)</td></tr><tr><td>happy</td><td>348 (36.9)</td></tr><tr><td>No response</td><td>10 (1.1)</td></tr><tr><td>Smoking</td><td></td></tr><tr><td>No</td><td>925 (98.0)</td></tr><tr><td><5 cigarettes per day</td><td>11 (1.2)</td></tr><tr><td>6 ~ 10 ci... |
53cda5a4147d2039c24fe6b2733ac8017a4f49b4b839f12ddc1292ab9045a5cc.png | complex | <table><tr><td rowspan="2"></td><td>Total Median Costs</td><td></td><td></td><td></td><td>MRI</td><td></td><td>No MRI</td><td></td></tr><tr><td colspan="4">(<i>N</i> = 53,653)</td><td colspan="2">(<i>N</i> = 10,776)</td><td colspan="2">(<i>N</i> = 42,877)</td></tr><tr><td>Characteristics<sup>b</sup> of women</td><td>N<... | <table><tr><td rowspan="2"></td><td>Total Median Costs</td><td></td><td></td><td></td><td>MRI</td><td></td><td>No MRI</td><td></td></tr><tr><td colspan="4">(N = 53,653)</td><td colspan="2">(N = 10,776)</td><td colspan="2">(N = 42,877)</td></tr><tr><td>Characteristicsb of women</td><td>N</td><td>%</td><td>Median</td><td... | <table><tr><td rowspan="2"></td><td>Total Median Costs</td><td></td><td></td><td></td><td>MRI</td><td></td><td>No MRI</td><td></td></tr><tr><td colspan="4">(N = 53,653)</td><td colspan="2">(N = 10,776)</td><td colspan="2">(N = 42,877)</td></tr><tr><td>Characteristicsb of women</td><td>N</td><td>%</td><td>Median</td><td... |
39f134e0b5c80700b46267f05160cc8ca5a1953e43113bb81429f7a75f8457b6.png | simple | <table><tr><td>Reason of Intake</td><td>Cat</td><td>Dog</td></tr><tr><td>Stray</td><td>100 (80.6%)</td><td>58 (47.5%)</td></tr><tr><td>People Issues (allergic, relocating, etc.)</td><td>5 (4.0%)</td><td>16 (13.1%)</td></tr><tr><td>Deceased Caretaker</td><td>3 (2.4%)</td><td>1 (0.8%)</td></tr><tr><td>Negligence</td><td>... | <table><tr><td>Reason of Intake</td><td>Cat</td><td>Dog</td></tr><tr><td>Stray</td><td>100 (80.6%)</td><td>58 (47.5%)</td></tr><tr><td>People Issues (allergic, relocating, etc.)</td><td>5 (4.0%)</td><td>16 (13.1%)</td></tr></table> | <table><tr><td>Deceased Caretaker</td><td>3 (2.4%)</td><td>1 (0.8%)</td></tr><tr><td>Negligence</td><td>2 (1.6%)</td><td>0 (0%)</td></tr><tr><td>Abandoned (chip and no reclaim)</td><td>0 (0%)</td><td>9 (7.4%)</td></tr><tr><td>Animal Illness</td><td>13 (10.5%)</td><td>27 (22.1%)</td></tr><tr><td>Behavior</td><td>1 (11.9... |
7385c8fe1af7e5548cc3311b922a637e7b721de44e136d648434dbdcc96836b2.png | simple | <table><tr><td>Time steps</td><td>Experiment-1</td><td>Experiment-2</td><td>Experiment-3</td><td>Experiment-4</td></tr><tr><td><i>t</i><sub>0</sub></td><td>75.12%</td><td>92.80%</td><td>55.02%</td><td>67.90%</td></tr><tr><td><i>t</i><sub>1</sub></td><td>78.07%</td><td>95.40%</td><td>80.01%</td><td>72.42%</td></tr><tr><... | <table><tr><td>Time steps</td><td>Experiment-1</td><td>Experiment-2</td></tr><tr><td>t0</td><td>75.12%</td><td>92.80%</td></tr><tr><td>t1</td><td>78.07%</td><td>95.40%</td></tr><tr><td>t2</td><td>78.39%</td><td>94.64%</td></tr><tr><td>t3</td><td>78.76%</td><td>95.56%</td></tr><tr><td>t4</td><td>78.33%</td><td>95.89%</t... | <table><tr><td>Experiment-3</td><td>Experiment-4</td></tr><tr><td>55.02%</td><td>67.90%</td></tr><tr><td>80.01%</td><td>72.42%</td></tr><tr><td>75.42%</td><td>53.79%</td></tr><tr><td>95.72%</td><td>61.30%</td></tr><tr><td>79.17%</td><td>55.70%</td></tr><tr><td>31.97%</td><td>68.11%</td></tr><tr><td>66.80%</td><td>72.33... |
0d4061eb372ecbcf9be5875c374e79c96c424a1cacb8f57bd30394ee48d890ff.png | complex | <table><tr><td>Target</td><td>Species</td><td>Dilution</td><td>Reference</td></tr><tr><td colspan="4">Primary antibodies</td></tr><tr><td> Nrf2</td><td>Rabbit</td><td>1:100</td><td>ab31163; Abcam, UK</td></tr><tr><td> AhR</td><td>Rabbit</td><td>1:200</td><td>sc-5579; H-211; Santa Cruz, Heidelberg, Germany</td></tr><tr>... | <table><tr><td>Target</td><td>Species</td><td>Dilution</td><td>Reference</td></tr><tr><td colspan="4">Primary antibodies</td></tr><tr><td>Nrf2</td><td>Rabbit</td><td>1:100</td><td>ab31163; Abcam, UK</td></tr><tr><td>AhR</td><td>Rabbit</td><td>1:200</td><td>sc-5579; H-211; Santa Cruz, Heidelberg, Germany</td></tr><tr><t... | <table><tr><td>Target</td><td>Species</td><td>Dilution</td><td>Reference</td></tr><tr><td colspan="4">ndary antibodies</td></tr><tr><td>Anti-rabbit</td><td>Goat</td><td>1:2000</td><td>AS09 633; Agrisera, Vännas, Sweden</td></tr></table> |
79409dac05db8ada4d3d6f873f18a11ff09224f500e4d32b824c6c03c0c836e6.png | complex | <table><tr><td> </td><td colspan="2">1a</td><td> </td><td colspan="2">7b</td></tr><tr><td>Position</td><td><i>δ</i><sub>C</sub></td><td><i>δ</i><sub>H</sub> (<i>J</i> Hz)</td><td>Position</td><td><i>δ</i><sub>C</sub></td><td><i>δ</i><sub>H</sub> (<i>J</i> Hz)</td></tr><tr><td>1a</td><td>43.8</td><td... | <table><tr><td></td><td colspan="2">1a</td><td></td><td colspan="2">7b</td></tr><tr><td>Position</td><td>δC</td><td>δH (J Hz)</td><td>Position</td><td>δC</td><td>δH (J Hz)</td></tr><tr><td>1a</td><td>43.8</td><td>1.12, m</td><td>2</td><td>161.6</td><td></td></tr><tr><td>1b</td><td></td><td>1.18, m</td><td>3</td><td>87.... | <table><tr><td>4′</td><td>129.6</td><td>7.48, d (8.0)</td><td></td><td></td><td></td></tr><tr><td>5′</td><td>134.1</td><td>7.60, t (7.5)</td><td></td><td></td><td></td></tr><tr><td>6′</td><td>129.6</td><td>7.47, d (7.5)</td><td></td><td></td><td></td></tr><tr><td>7′</td><td>130.6</td><td>7.97, dd (1.5,7.0)</td><td></td... |
7ec2619cc8d54d69ebc622cbc55b254a8e871d93b6ed9fef88026a398acd4165.png | simple | <table><tr><td>Tumor and normal cells</td><td>Cis-3M-RESIC<sub>50</sub> (μM)<sup>*</sup></td><td>ResveratrolIC<sub>50</sub> (μM)<sup>*</sup></td></tr><tr><td>Unstimulated human peripheral T cells</td><td>>10.0</td><td>N.D</td></tr><tr><td>PHA-stimulated human peripheral T cells<sup>**</sup></td><td>0.23</t... | <table><tr><td>Tumor and normal cells</td></tr><tr><td>Unstimulated human peripheral T cells</td></tr><tr><td>PHA-stimulated human peripheral T cells**</td></tr><tr><td>Human acute T cell leukemia Jurkat E6.1</td></tr><tr><td>Human acute T cell leukemia Jurkat (JT/Neo)</td></tr><tr><td>Human acute T cell leukemia Jurka... | <table><tr><td>Cis-3M-RESIC50 (μM)*</td><td>ResveratrolIC50 (μM)*</td></tr><tr><td>>10.0</td><td>N.D</td></tr><tr><td>0.23</td><td>N.D</td></tr><tr><td>0.07</td><td>110.1</td></tr><tr><td>0.08</td><td>97.5</td></tr><tr><td>>10.0</td><td>>250.0</td></tr><tr><td>0.08</td><td>86.6</td></tr><tr><td>0.08</td><td>60.5</td></... |
d40bfefd7ccad9ceab6e894d6ec8b99dd6b75fac022a1275cf1633cbddb99af3.png | simple | <table><tr><td>Variable</td><td>Categories</td><td>Unadjusted Odd ratio (CI)</td></tr><tr><td>Fistula size</td><td>Large (> 3 cm)</td><td>5.33(0.93-30.50)</td></tr><tr><td></td><td>Medium (1-3 cm)</td><td>0.63(1.39-2.86)</td></tr><tr><td></td><td>Small (< 3 cm)</td><td>1</td></tr><tr><td>Level of vaginal scarring... | <table><tr><td>Variable</td><td>Categories</td><td>Unadjusted Odd ratio (CI)</td></tr><tr><td>Fistula size</td><td>Large (> 3 cm)</td><td>5.33(0.93-30.50)</td></tr><tr><td></td><td>Medium (1-3 cm)</td><td>0.63(1.39-2.86)</td></tr><tr><td></td><td>Small (< 3 cm)</td><td>1</td></tr><tr><td>Level of vaginal scarring</td><... | <table><tr><td>Variable</td><td>Categories</td><td>Unadjusted Odd ratio (CI)</td></tr><tr><td></td><td>Urethral involvement</td><td></td></tr><tr><td></td><td>No urethral involvement</td><td>1</td></tr><tr><td>Class of Fistula</td><td>Type II b</td><td>5.56(1.34-23.02)*</td></tr><tr><td></td><td>Type II a</td><td>O.625... |
bdc9ec0d0cd0ce381b73aff8a30be0b228233e8b0f1dc42daeceec476e71fd4f.png | complex | <table><tr><td></td><td>Adult <i>n</i> (%) (<i>n</i> = 186)<sup>a</sup></td><td>Paediatric <i>n</i> (%) (<i>n</i> = 17)<sup>a</sup></td><td><i>p</i>-value</td></tr><tr><td>Pulmonary TB</td><td>125 (67)</td><td>14 (82)</td><td>0.198</td></tr><tr><td> Multidrug-resistant TB</td><td>7 (6)</td><td>2 (14)</td><td>0.099</td>... | <table><tr><td></td><td>Adult n (%) (n = 186)a</td><td>Paediatric n (%) (n = 17)a</td><td>p-value</td></tr><tr><td>Pulmonary TB</td><td>125 (67)</td><td>14 (82)</td><td>0.198</td></tr><tr><td>Multidrug-resistant TB</td><td>7 (6)</td><td>2 (14)</td><td>0.099</td></tr><tr><td colspan="4">Method TB detected</td></tr><tr><... | <table><tr><td></td><td>Adult n (%) (n = 186)a</td><td>Paediatric n (%) (n = 17)a</td><td>p-value</td></tr><tr><td>Reception centre in Finland</td><td>27 (15)</td><td>8 (47)</td><td><0.01</td></tr><tr><td>Refugee camp abroad</td><td>25 (13)</td><td>5 (29)</td><td>0.076</td></tr><tr><td>No TB-related symptoms</td><td>40... |
c1c0c92e3c70740dc067896ea690521b088f751521ed71334965fb3f7694b899.png | simple | <table><tr><td> ISTH score</td><td>Predicted score from PT</td><td>Predicted score from PT + APTT</td><td>Predicted score from PT/APTT</td></tr><tr><td>2</td><td>3.44</td><td>3.37</td><td>3.70</td></tr><tr><td>2</td><td>3.48</td><td>3.49</td><td>3.43</td></tr><tr><td>2</td><td>3.34</td><td>3.31</td><td>3.29</td></tr><t... | <table><tr><td>ISTH </td><td>Predicted score fr</td><td>Predicted score from PT + AP</td><td>Predicted score fro</td></tr></table> | <table><tr><td>score</td><td>om PT</td><td>TT</td><td>m PT/APTT</td></tr><tr><td>2</td><td>3.44</td><td>3.37</td><td>3.70</td></tr><tr><td>2</td><td>3.48</td><td>3.49</td><td>3.43</td></tr><tr><td>2</td><td>3.34</td><td>3.31</td><td>3.29</td></tr><tr><td>2</td><td>3.34</td><td>3.31</td><td>3.29</td></tr><tr><td>2</td><... |
49285aa3003552accc7dbcd8b5d251fd4308d6bc784eb74eb5e0900cf0a59614.png | complex | <table><tr><td>Scale</td><td colspan="3">Men</td><td colspan="3">Women</td><td><i>d</i> (Men-Women)</td></tr><tr><td></td><td>α</td><td><i>M</i></td><td><i>SD</i></td><td>α</td><td><i>M</i></td><td><i>SD</i></td><td></td></tr><tr><td>Vigor</td><td>0.89</td><td>3.03</td><td>0.89</td><td>0.88</td><td>2.87</td><... | <table><tr><td>Scale</td><td colspan="3">Men</td><td colspan="3">Women</td></tr><tr><td></td><td>α</td><td>M</td><td>SD</td><td>α</td><td>M</td><td>SD</td></tr><tr><td>Vigor</td><td>0.89</td><td>3.03</td><td>0.89</td><td>0.88</td><td>2.87</td><td>0.91</td></tr><tr><td>Calmness</td><td>0.88</td><td>3.90</td><td>0.66</td... | <table><tr><td>d (Men-Women)</td></tr><tr><td></td></tr><tr><td>0.17</td></tr><tr><td>0.00</td></tr><tr><td>−0.05</td></tr><tr><td>0.18</td></tr><tr><td>0.41</td></tr><tr><td>−0.32</td></tr><tr><td>0.06</td></tr><tr><td>0.29</td></tr><tr><td>−0.42</td></tr><tr><td>−0.17</td></tr></table> |
9ad4cc74acef76c4b6d88aa3241b4719fcc40379cfd225d90f0723ecfd213c76.png | complex | <table><tr><td colspan="2"> </td><td>All participants(<i>N</i> = 2,467)</td></tr><tr><td colspan="2">Age, years</td><td>58.3 (15.7)</td></tr><tr><td colspan="2">Sex, women, <i>n</i></td><td>1,438 (58.3%)</td></tr><tr><td colspan="2">Regular exercise,<sup>a</sup><i>n</i></td><td>831 (33.8%)</td></tr><tr><td>Smoking</td>... | <table><tr><td></td></tr><tr><td>Age, years</td></tr><tr><td>Sex, women, n</td></tr><tr><td>Regular exercise,an</td></tr><tr><td>Smoking</td></tr><tr><td></td></tr><tr><td>Alcohol consumption, g/week</td></tr><tr><td>Body mass index, kg/m2</td></tr><tr><td>Systolic blood pressure, mm Hg</td></tr><tr><td>Diastolic blood... | <table><tr><td></td><td>All participants(N = 2,467)</td></tr><tr><td>Age, years</td><td>58.3 (15.7)</td></tr><tr><td>Sex, women, n</td><td>1,438 (58.3%)</td></tr><tr><td>Regular exercise,an</td><td>831 (33.8%)</td></tr><tr><td>Current smoker, n</td><td>381 (15.5%)</td></tr><tr><td>Ex-smoker, n</td><td>460 (18.7%)</td><... |
21b25826035432386722bd00b194f3d301024c386e263f06d6010144a911c70d.png | simple | <table><tr><td>Characteristic</td><td>No. of participants (<i>n</i> = 15)</td></tr><tr><td>Age [median (range)]</td><td>47 (33–59)</td></tr><tr><td>Sex</td><td></td></tr><tr><td>Male</td><td>8</td></tr><tr><td>Female</td><td>7</td></tr><tr><td>Ethnicity</td><td></td></tr><tr><td>White British</td><td>13</td></tr>... | <table><tr><td>Characteristic</td></tr><tr><td>Age [median (range)]</td></tr><tr><td>Sex</td></tr><tr><td>Male</td></tr><tr><td>Female</td></tr><tr><td>Ethnicity</td></tr><tr><td>White British</td></tr><tr><td>Other</td></tr><tr><td>Profession</td></tr><tr><td>Surgeon</td></tr><tr><td>Clinical oncologist</td></tr><tr><... | <table><tr><td>No. of participants (n = 15)</td></tr><tr><td>47 (33–59)</td></tr><tr><td></td></tr><tr><td>8</td></tr><tr><td>7</td></tr><tr><td></td></tr><tr><td>13</td></tr><tr><td>2</td></tr><tr><td></td></tr><tr><td>5</td></tr><tr><td>3</td></tr><tr><td>4</td></tr><tr><td>1</td></tr><tr><td>1</td></tr><tr><td>1</td... |
0f8f8eba032d6ac99c875a2af0d95de31ad4e835caa0054ca30b92feccf5dc25.png | complex | <table><tr><td rowspan="2"></td><td colspan="2">Ethiopia</td><td colspan="2">Kenya</td></tr><tr><td>Urban</td><td>Rural</td><td>Urban</td><td>Rural</td></tr><tr><td>Age</td><td></td><td></td><td></td><td></td></tr><tr><td> 15–24</td><td>15.9</td><td>15.9</td><td>12.5</td><td>10.3</td></tr><tr><td> 25–34</td... | <table><tr><td rowspan="2"></td><td colspan="2">Ethiopia</td><td colspan="2">Kenya</td></tr><tr><td>Urban</td><td>Rural</td><td>Urban</td><td>Rural</td></tr><tr><td>Age</td><td></td><td></td><td></td><td></td></tr><tr><td>15–24</td><td>15.9</td><td>15.9</td><td>12.5</td><td>10.3</td></tr><tr><td>25–34</td><td>37.3</td>... | <table><tr><td rowspan="2"></td><td colspan="2">Ethiopia</td><td colspan="2">Kenya</td></tr><tr><td>Urban</td><td>Rural</td><td>Urban</td><td>Rural</td></tr><tr><td>Education</td><td></td><td></td><td></td><td></td></tr><tr><td>Nil</td><td>12.9</td><td>49.0</td><td>14.0</td><td>16.0</td></tr><tr><td>Primary</td><td>40.... |
65743b0ce55a789cc9169a3b02acd0f88f574a30dc5c4c3cedb6dcbdc4550e28.png | complex | <table><tr><td>Data</td><td>Characteristics</td><td>Description</td></tr><tr><td rowspan="3">Classes of deprivation</td><td>Group 1: low deprivation</td><td>Census block with high median income, low proportion of households without a car, low proportion with non-owner-occupied primary residences</td></tr><tr><td>Group ... | <table><tr><td>Data</td><td>Characteristics</td><td>Description</td></tr><tr><td rowspan="2">Classes of deprivation</td><td>Group 1: low deprivation</td><td>Census block with high median income, low proportion of households without a car, low proportion with non-owner-occupied primary residences</td></tr><tr><td>Group ... | <table><tr><td>Classes of deprivation</td><td>Group 3: high deprivation</td><td>Census block with low median income, high proportion of households without a car, high proportion with non-owner-occupied primary residences</td></tr></table> |
ca07b1f1fa34fb65011864367c298872676e891c63eed51a8d97c2a0d6da20da.png | complex | <table><tr><td></td><td></td><td></td><td colspan="2">95% Confidence Interval for odds</td></tr><tr><td></td><td>P value</td><td>OR</td><td>Lower</td><td>Upper</td></tr><tr><td>Gender(female)</td><td></td><td></td><td>1.259</td><td>5.725</td></tr><tr><td>Jobless</td><td><.001</td><td>1.870</td><td>1.412</td><td>2.47... | <table><tr><td></td><td></td><td></td><td colspan="2">95% Confidence Interval for odds</td></tr><tr><td></td><td>P value</td><td>O</td><td>L</td><td>Uppe</td></tr></table> | <table><tr><td></td><td></td><td>R</td><td>ower</td><td>r</td></tr><tr><td>Gender(female)</td><td></td><td></td><td>1.259</td><td>5.725</td></tr><tr><td>Jobless</td><td><.001</td><td>1.870</td><td>1.412</td><td>2.478</td></tr><tr><td>Illegal Income</td><td>.001</td><td>1.617</td><td>1.217</td><td>2.150</td></tr><tr><td... |
c8eaf89bb451435fc6376374d0370e126a01eebe043598efb32bb86835c342c5.png | complex | <table><tr><td></td><td colspan="4">Position at foot contact (deg)</td></tr><tr><td></td><td>Flexion</td><td>Ext. tibial rot.</td><td colspan="2">Varus</td></tr><tr><td>ICC</td><td>0.93</td><td>0.94</td><td colspan="2">0.95</td></tr><tr><td>SEM (deg)</td><td>1.80</td><td>1.42</td><td colspan="2">0.61</td></tr><tr><td><... | <table><tr><td></td><td colspan="4">Position at foot contact (deg)</td></tr><tr><td></td><td>Flexion</td><td>Ext. tibial rot.</td><td colspan="2">Varus</td></tr><tr><td>ICC</td><td>0.93</td><td>0.94</td><td colspan="2">0.95</td></tr></table> | <table><tr><td></td><td colspan="4">Position at foot contact (deg)</td></tr><tr><td>SEM (deg)</td><td>1.80</td><td>1.42</td><td colspan="2">0.61</td></tr><tr><td></td><td colspan="4">Displacement during landing (deg)</td></tr><tr><td></td><td>Flexion</td><td>Int. tibial rot.</td><td>Varus</td><td>Valgus</td></tr><tr><t... |
26c8d51ee97393aa2429bc008432a43f191fec1b403ff520546fd64a33757bf5.png | simple | <table><tr><td></td><td>Metric</td><td><i>F</i></td><td><i>R</i><sup>2</sup></td><td><i>p</i> value*</td></tr><tr><td>HC (<i>n</i> = 29)vsRTT (<i>n</i> = 50)</td><td>Unweighted UniFrac</td><td>6.84</td><td>0.08</td><td>≤0.003</td></tr><tr><td></td><td>Weighted UniFrac</td><td>15.6</td><td>0.16</td><td>≤0.00... | <table><tr><td></td><td>Metric</td><td>F</td><td>R2</td><td>p value*</td></tr><tr><td>HC (n = 29)vsRTT (n = 50)</td><td>Unweighted UniFrac</td><td>6.84</td><td>0.08</td><td>≤0.003</td></tr><tr><td></td><td>Weighted UniFrac</td><td>15.6</td><td>0.16</td><td>≤0.003</td></tr><tr><td></td><td>Bray-Curtis</td><td>6.94</td><... | <table><tr><td>RTT-C (n = 34)vsRTT-NC (n = 14)</td><td>Unweighted UniFrac</td><td>1.31</td><td>0.02</td><td>0.180</td></tr><tr><td></td><td>Weighted UniFrac</td><td>1.10</td><td>0.02</td><td>0.687</td></tr><tr><td></td><td>Bray-Curtis</td><td>1.76</td><td>0.03</td><td>0.180</td></tr></table> |
4f9dc11712b09d0a7d6e90e54df26f9910a0c6896e4bad3fc7185527bb585da7.png | complex | <table><tr><td></td><td></td><td>CECA22*</td><td>CECA10</td><td>CECA6</td><td>CECA4</td></tr><tr><td colspan="2">N° of items</td><td>22</td><td>10</td><td>6</td><td>4</td></tr><tr><td colspan="2">Scoring distribution</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">Valid observations</td><td>132</t... | <table><tr><td></td><td></td><td>CECA22*</td><td>CECA10</td><td>CECA6</td><td>CECA4</td></tr><tr><td colspan="2">N° of items</td><td>22</td><td>10</td><td>6</td><td>4</td></tr><tr><td colspan="2">Scoring distribution</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">Valid observations</td><td>132</td><td... | <table><tr><td></td><td></td><td>CECA22*</td><td>CECA10</td><td>CECA6</td><td>CECA4</td></tr><tr><td colspan="2">scoring 100</td><td>0</td><td>1</td><td></td><td>(5.9%)</td></tr><tr><td colspan="2">Correlation item-global scoring</td><td>0.21–0.72</td><td>0.53–0.73</td><td>0.65–0.79</td><td>0.78–0.89</td></tr><tr><td c... |
bde03731d9c8752a3742857fd39619c1930069c52e7a10802356251891cbda84.png | simple | <table><tr><td></td><td>Insomnia (<i>N</i> = 17)</td><td>Controls (<i>N</i> = 15)</td><td><i>p</i>-values</td></tr><tr><td>HbA1c (%)</td><td>5.3 (0.3)</td><td>5.4 (0.3)</td><td>>0.05</td></tr><tr><td>Fasting blood glucose (mg/dl)</td><td>97.6 (8.2)</td><td>96.3 (10.3)</td><td>>0.05</td></tr><tr><td>Blood glucose ... | <table><tr><td></td><td>Insomnia (N = 17)</td><td>Controls (N = 15)</td><td>p-values</td></tr></table> | <table><tr><td>HbA1c (%)</td><td>5.3 (0.3)</td><td>5.4 (0.3)</td><td>>0.05</td></tr><tr><td>Fasting blood glucose (mg/dl)</td><td>97.6 (8.2)</td><td>96.3 (10.3)</td><td>>0.05</td></tr><tr><td>Blood glucose after 30 min (mg/dl)</td><td>138.7 (22.1)</td><td>156. 9 (30.3)</td><td>>0.05</td></tr><tr><td>Blood glucose after... |
a66f46c43900efdb7ca3ab1df1d49aa668bd745844b7831549e85b1243043223.png | simple | <table><tr><td>Toxicity</td><td>Grade</td><td>ACRT</td><td>STRT1</td><td>STRT2</td><td>Total</td><td><i>p</i>-value</td></tr><tr><td></td><td></td><td>(45 Gy)</td><td>(60-63 Gy)</td><td>(> 63 Gy)</td><td></td><td></td></tr><tr><td></td><td></td><td>n = 154</td><td>n = 99</td><td>n = 239</td><td></td><td></td></tr><t... | <table><tr><td>Toxicity</td><td>Grade</td><td>ACRT</td><td>STRT1</td><td>STRT2</td><td>Total</td><td>p-value</td></tr><tr><td></td><td></td><td>(45 Gy)</td><td>(60-63 Gy)</td><td>(> 63 Gy)</td><td></td><td></td></tr><tr><td></td><td></td><td>n = 154</td><td>n = 99</td><td>n = 239</td><td></td><td></td></tr><tr><td>Esop... | <table><tr><td>Grade</td><td>ACRT</td><td>STRT1</td><td>STRT2</td><td>Total</td></tr><tr><td></td><td>(45 Gy)</td><td>(60-63 Gy)</td><td>(> 63 Gy)</td><td></td></tr><tr><td></td><td>n = 154</td><td>n = 99</td><td>n = 239</td><td></td></tr><tr><td>≥ 2</td><td>4(3.4%)</td><td>9(10.0%)</td><td>1(1.1%)</td><td>14(4.7%)</td... |
e1d1f80626cf58259487b9ebf1578afd8bb947aa1feab4f51d40d5cb36fc8b38.png | simple | <table><tr><td>S. No</td><td>Lubricant</td><td>Speed (kmph)</td><td>Load (N)</td></tr><tr><td>1</td><td>Racer-4</td><td>40-60</td><td>10-50</td></tr><tr><td>2</td><td>Racer-4 + 0.05% Cu</td><td>40-60</td><td>20-80</td></tr><tr><td>3</td><td>Racer-4 + 0.1% Cu</td><td>40-60</td><td>20-80</td></tr><tr><td>4</td><td>Racer-... | <table><tr><td>S. No</td><td>Lubricant</td><td>Speed (kmph)</td><td>Load (N)</td></tr><tr><td>1</td><td>Racer-4</td><td>40-60</td><td>10-50</td></tr></table> | <table><tr><td>S. No</td><td>Lubricant</td><td>Speed (kmph)</td><td>Load (N)</td></tr><tr><td>2</td><td>Racer-4 + 0.05% Cu</td><td>40-60</td><td>20-80</td></tr><tr><td>3</td><td>Racer-4 + 0.1% Cu</td><td>40-60</td><td>20-80</td></tr><tr><td>4</td><td>Racer-4 + 0.2% Cu</td><td>40-60</td><td>20-80</td></tr><tr><td>5</td>... |
d0455f7f1045812c43caf3caa0253c58a45911f59647bce413045538321b6ab1.png | complex | <table><tr><td>Factors</td><td colspan="2">Simple regression</td><td colspan="3">Multiple regression</td></tr><tr><td> </td><td>Unstandardizedcoefficient(B)</td><td>P value</td><td>Unstandardizedcoefficient(B)</td><td>Standardizedcoefficient(beta)</td><td>P value</td></tr><tr><td>Gly1057Asp polymorphism in IRS-2</td><t... | <table><tr><td>Factors</td><td colspan="2">Simple regression</td><td colspan="3">Multiple regression</td></tr><tr><td></td><td>Unstandardizedcoefficient(B)</td><td>P value</td><td>Unstandardizedcoefficient(B)</td><td>Standardizedcoefficient(beta)</td><td>P value</td></tr><tr><td>Gly1057Asp polymorphism in IRS-2</td><td... | <table><tr><td>Factors</td><td colspan="2">Simple regression</td><td colspan="3">Multiple regression</td></tr><tr><td></td><td>Unstandardizedcoefficient(B)</td><td>P value</td><td>Unstandardizedcoefficient(B)</td><td>Standardizedcoefficient(beta)</td><td>P value</td></tr><tr><td>n = 69) + Gly/Asp(n = 80)</td><td>0.007<... |
0ad0c0d2dad0e58b7167353448a1d3e405d0dabdbdef6d875875a6a0c1ebdd06.png | complex | <table><tr><td rowspan="3">Spice</td><td colspan="6">Frequency of dishes prepared</td></tr><tr><td colspan="2">Daily</td><td colspan="2">Weekly</td><td colspan="2">Monthly</td></tr><tr><td>N</td><td>Intake mean ± S.D (Median)</td><td>N</td><td>Intake mean ± S.D (Median)</td><td>N</td><td>Intake mean ± S.... | <table><tr><td rowspan="3">Spice</td><td colspan="6">Frequency of dishes prepared</td></tr><tr><td colspan="2">Daily</td><td colspan="2">Weekly</td><td colspan="2">Monthly</td></tr><tr><td>N</td><td>Intake mean ± S.D (Median)</td><td>N</td><td>Intake mean ± S.D (Median)</td><td>N</td><td>Intake mean ± S.D (Median)</td>... | <table><tr><td>Fenugreek</td><td>-</td><td>-</td><td>25</td><td>0.68 ± 0.65 (0.4)</td><td>4</td><td>2.04</td></tr><tr><td>Carom seeds</td><td>-</td><td>-</td><td>13</td><td>0.69 ± 0.64 (0.45)</td><td>5</td><td>0.66</td></tr></table> |
1f704a92d2e1e9cca9fe78076d42c9e96bcb29311ae00c82d502421fe9b7beed.png | simple | <table><tr><td> </td><td>NC</td><td>MCI</td><td>AD</td></tr><tr><td>NC</td><td>15/16</td><td>1/1</td><td>0/0</td></tr><tr><td>MCI</td><td>2/1</td><td>14/16</td><td>3/1</td></tr><tr><td>AD</td><td>0/0</td><td>3/1</td><td>14/16</td></tr></table> | <table><tr><td></td><td>NC</td><td>MCI</td><td>AD</td></tr><tr><td>NC</td><td>15/16</td><td>1/1</td><td>0/0</td></tr><tr><td>MCI</td><td>2/1</td><td>14/16</td><td>3/1</td></tr><tr><td>AD</td><td>0/</td><td></td><td>1</td></tr></table> | <table><tr><td></td><td>NC</td><td>MCI</td><td>AD</td></tr><tr><td></td><td>0</td><td>3/1</td><td>4/16</td></tr></table> |
28ab9395f57c2ef3d41d97c508f9b209023c09a236eaea00f557f7f15ab8c6c7.png | complex | <table><tr><td>Category</td><td>Part A</td><td>Part B</td><td>Part C</td><td>Total</td></tr><tr><td rowspan="2">Preferred Term</td><td>(<i>N</i> = 12)</td><td>(<i>N</i> = 10)</td><td>(<i>N</i> = 10)</td><td>(<i>N</i> = 32)</td></tr><tr><td>N (%)</td><td>N (%)</td><td>N (%)</td><td>N (%)</td></tr><tr><td>Subjects with A... | <table><tr><td>Category</td><td>Part A</td><td>Part B</td><td>Part C</td><td>Total</td></tr><tr><td rowspan="2">Preferred Term</td><td>(N = 12)</td><td>(N = 10)</td><td>(N = 10)</td><td>(N = 32)</td></tr><tr><td>N (%)</td><td>N (%)</td><td>N (%)</td><td>N (%)</td></tr><tr><td></td><td>1 (8.</td><td>3</td><td>7 (70.0)</... | <table><tr><td>Category</td><td>Part A</td><td>Part B</td><td>Part C</td><td>Total</td></tr><tr><td rowspan="2">Preferred Term</td><td>(N = 12)</td><td>(N = 10)</td><td>(N = 10)</td><td>(N = 32)</td></tr><tr><td>N (%)</td><td>N (%)</td><td>N (%)</td><td>N (%)</td></tr><tr><td>Subjects with Any Adverse Event</td><td>3)<... |
f92145ebeb69407c1ab817972590e5d45a0807f3bd377d0d020c0e733f627ae4.png | simple | <table><tr><td></td><td>Phe-free milk</td><td>Phe-free amino acid powder (A-1)</td><td>Low Phe peptide powder (MP-11)</td></tr><tr><td>Protein (g)</td><td>15.8</td><td>93.7</td><td>75</td></tr><tr><td>Fat (g)</td><td>17.1</td><td>0</td><td>0</td></tr><tr><td>Carbohydrate (g)</td><td>60.4</td><td>0</td><td>7.2</td></tr>... | <table><tr><td></td><td>Phe-free milk</td><td>Phe-free amino acid powder (A-1)</td><td>Low Phe peptide powder (MP-11)</td></tr><tr><td>Protein (g)</td><td>15.8</td><td>93.7</td><td>75</td></tr><tr><td>Fat (g)</td><td>17.1</td><td>0</td><td>0</td></tr><tr><td>Carbohydrate (g)</td><td>60.4</td><td>0</td><td>7.2</td></tr>... | <table><tr><td></td><td>Phe-free milk</td><td>Phe-free amino acid powder (A-1)</td><td>Low Phe peptide powder (MP-11)</td></tr><tr><td>I (μg)</td><td>25</td><td>0</td><td>150</td></tr><tr><td>Se (μg)</td><td>1</td><td>2</td><td>11</td></tr><tr><td>Vit A (IU)</td><td>1500</td><td>0</td><td>0</td></tr><tr><td>Vit B1 (mg)... |
b0917f259b6ef369df22d690199c689e07a5579cac44674ec5ede18da4e91ce3.png | complex | <table><tr><td> </td><td colspan="2">Prevalence per 10,000</td><td colspan="2">Crude incidence per 10,000</td><td colspan="2">Mortality per 100,000</td><td colspan="2">Fatality per 1,000</td></tr><tr><td>Age</td><td>Rate</td><td>C.I. 95%</td><td>Rate</td><td>C.I. 95%</td><td>Rate</td><td>C.I. 95%</td><td>Rate</td><td>C... | <table><tr><td></td><td colspan="2">Prevalence per 10,000</td><td colspan="2">Crude incidence per 10,000</td><td colspan="2">Mortality per 100,000</td><td colspan="2">Fatality per 1,000</td></tr><tr><td>Age</td><td>Rate</td><td>C.I. 95%</td><td>Rate</td><td>C.I. 95%</td><td>Rate</td><td>C.I. 95%</td><td>Rate</td><td>C.... | <table><tr><td></td><td colspan="2">Prevalence per 10,000</td><td colspan="2">Crude incidence per 10,000</td><td colspan="2">Mortality per 100,000</td><td colspan="2">Fatality per 1,000</td></tr><tr><td>over 65 years</td><td>17.68</td><td>16.83-18.53</td><td>2.90</td><td>2.56-3.25</td><td>28.51</td><td>25.10-31.91</td>... |
2e189bc0a8b3f3f04b1f3dd5ff3a8883bb820c07a6db6148647e6f49596378f2.png | complex | <table><tr><td rowspan="2">Compound Administered</td><td rowspan="2">Subject ID</td><td colspan="2"><i>R-</i>baclofen (ng/mL) </td><td colspan="2"><i>S-</i>baclofen (ng/mL) </td><td colspan="2"><i>S-</i>M1 (ng/mL) </td></tr><tr><td>Plasma</td><td>Urine</td><td>Plasma</td><td>Urine</td><td>Plasma</td><td>Urine</td></tr>... | <table><tr><td rowspan="2">Compound Administered</td><td rowspan="2">Subject ID</td><td colspan="2">R-baclofen (ng/mL)</td><td colspan="2">S-baclofen (ng/mL)</td></tr><tr><td>Plasma</td><td>Urine</td><td>Plasma</td><td>Urine</td></tr><tr><td rowspan="7">Racemic Baclofen 10 mg</td><td>P1-01</td><td>45.2</td><td>1880</td... | <table><tr><td colspan="2">S-M1 (ng/mL)</td></tr><tr><td>Plasma</td><td>Urine</td></tr><tr><td>24.9</td><td>254</td></tr><tr><td>27.5</td><td>146</td></tr><tr><td>19.5</td><td>183</td></tr><tr><td>18.7</td><td>142</td></tr><tr><td>25.1</td><td>75.1</td></tr><tr><td>16.4</td><td>99.4</td></tr><tr><td>20.1</td><td>95</td... |
01e0785d8520e8d4c70ef62618b45678eb6a1bda0a495dbba058d91b5388c06e.png | simple | <table><tr><td></td><td>25 JIA patientswith secondary LOE</td><td>28 JIA patientswithout secondary LOE</td></tr><tr><td>median age (range)</td><td>14.4 (6.0-27.0) years</td><td>13.8 (7.6-21.5) years</td></tr><tr><td>Sex</td><td>21 female, 4 male</td><td>18 female, 10 male</td></tr><tr><td>median ADM dose (range)</td><t... | <table><tr><td></td><td>25 JIA patientswith secondary LOE</td><td>28 JIA patientswithout secondary LOE</td></tr><tr><td>median age (range)</td><td>14.4 (6.0-27.0) years</td><td>13.8 (7.6-21.5) years</td></tr></table> | <table><tr><td>Sex</td><td>21 female, 4 male</td><td>18 female, 10 male</td></tr><tr><td>median ADM dose (range)</td><td>25.8 (10.7-58.8) mg/m2 every other week</td><td>24.3 (6.6-37.1) mg/m2 every other week</td></tr><tr><td>median duration of anti-TNF therapy (range)</td><td>2.2 (0.2-6.0) years</td><td>1.3 (0.2-10.4) ... |
6a364e70dd1969dad09472c87f37afe3b4889f61f9928ae10c62bb8d5176c6ff.png | simple | <table><tr><td>ETIOLOGY</td><td>NO. OF PATIENTS</td><td>PERCENTAGE</td></tr><tr><td>ONCOLOGICAL RES.</td><td>75</td><td>42.1%</td></tr><tr><td>TMJ ANKYLOSIS</td><td>35</td><td>19.6%</td></tr><tr><td>POST-TRAUMATIC</td><td>44</td><td>24.7%</td></tr><tr><td>OSTEOMYELITIS OF MANDIBLE</td><td>24</td><td>13.5%</td></tr><tr>... | <table><tr><td>ETIOLOGY</td><td>NO. OF PATIENTS</td><td>PERCENTAGE</td></tr><tr><td>ONCOLOGICAL RES.</td><td>75</td><td>42.1%</td></tr><tr><td>TMJ ANKYLOSIS</td><td>35</td><td>19.6%</td></tr></table> | <table><tr><td>POST-TRAUMATIC</td><td>44</td><td>24.7%</td></tr><tr><td>OSTEOMYELITIS OF MANDIBLE</td><td>24</td><td>13.5%</td></tr><tr><td>TOTAL</td><td>178</td><td>100 %</td></tr></table> |
3bb89bcba0539bd0b616fae3ac782015caea7b6a62dbdea091e9ef8510c5af4f.png | simple | <table><tr><td>Factor</td><td>Estimate</td><td>SE</td><td>Chi-square</td><td><i>P</i> value</td></tr><tr><td>F14</td><td>0.0197</td><td>0.0184</td><td>1.14</td><td>0.2857</td></tr><tr><td>F3</td><td>0.1558</td><td>0.0304</td><td>26.34</td><td><0.0001</td></tr><tr><td>F9</td><td>0.0498</td><td>0.0185</td><td>7.22</td... | <table><tr><td>Factor</td></tr><tr><td>F14</td></tr><tr><td>F3</td></tr><tr><td>F9</td></tr></table> | <table><tr><td>Estimate</td><td>SE</td><td>Chi-square</td><td>P value</td></tr><tr><td>0.0197</td><td>0.0184</td><td>1.14</td><td>0.2857</td></tr><tr><td>0.1558</td><td>0.0304</td><td>26.34</td><td><0.0001</td></tr><tr><td>0.0498</td><td>0.0185</td><td>7.22</td><td>0.0072</td></tr></table> |
79ee8e401c979524f2174a03629bb6ee38aee278bae8bfb2b96473d24ba97ebf.png | complex | <table><tr><td rowspan="2"></td><td colspan="2">PM6</td><td colspan="2">PM7</td></tr><tr><td>E (kcal/mol)</td><td>∆E (kcal/mol)</td><td>E (kcal/mol)</td><td>∆E (kcal/mol)</td></tr><tr><td><i>Isolated molecule</i></td><td></td><td></td><td></td><td></td></tr><tr><td>Plumbagin</td><td>−84.56</td><td></t... | <table><tr><td rowspan="2"></td><td colspan="2">PM6</td><td colspan="2">PM7</td></tr><tr><td>E (kcal/mol)</td><td>∆E (kcal/mol)</td><td>E (kcal/mol)</td><td>∆E (kcal/mol)</td></tr><tr><td>Isolated molecule</td><td></td><td></td><td></td><td></td></tr><tr><td>Plumbagin</td><td>−84.56</td><td></td><td>−87.09</td><td></td... | <table><tr><td>MBCD-I–MBCD-II</td><td></td><td>4.75</td><td></td><td>−3.24</td></tr><tr><td>HPBCD-I</td><td>−1753.57</td><td>−9.08</td><td>−1820.19</td><td>−31.21</td></tr><tr><td>HPBCD-II</td><td>−1750.20</td><td>−5.70</td><td>−1829.73</td><td>−40.75</td></tr><tr><td>HPBCD-I–HPBCD-II</td><td></td><td>−3.38</td><td></t... |
4e38fb8255717b7151af9fd219fbacda737d7860013ba2e439413192bd8bfae3.png | complex | <table><tr><td> </td><td><i>Control</i></td><td><i>Intervention</i></td><td><i>Comparison</i></td><td><i>Treatment effect</i></td><td><i>P value</i></td></tr><tr><td>Maternal</td><td>n = 75</td><td>n = 79</td><td> </td><td>(95% CI)</td><td> </td></tr><tr><td>GDM</td><td>24 (32%)</td><td>22 (28%)</td><td>Risk difference... | <table><tr><td></td><td>Control</td><td>Intervention</td><td>Comparison</td><td>Treatment effect</td><td>P value</td></tr><tr><td>Maternal</td><td>n = 75</td><td>n = 79</td><td></td><td>(95% CI)</td><td></td></tr><tr><td>GDM</td><td>24 (32%)</td><td>22 (28%)</td><td>Risk difference</td><td>−4% (−19 to 13)</td><td>0.574... | <table><tr><td>>4 Kg</td><td>16 (19%)</td><td>13 (15%)</td><td>Risk difference</td><td>−4% (−15 to 8)</td><td>0.518</td></tr></table> |
bb93a2ed6ac8034ba5626f2d54ea43315954f29e10dc23cb9c23931d69d88575.png | simple | <table><tr><td>Green alga/land plant</td><td>Size (bp)</td><td>IR size (bp)</td><td>Genes (no.) <sup>a</sup></td><td>Introns (no.) <sup>b</sup></td><td>GenBank accession no.</td></tr><tr><td>Charophyceae</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><i>Chara vulgaris</i></td><td>184,933</td><td>10,919</... | <table><tr><td>Green alga/land plant</td></tr><tr><td>Charophyceae</td></tr><tr><td>Chara vulgaris</td></tr><tr><td>Chaetosphaeridium globosum</td></tr><tr><td>Chlorokybus atmophyticus</td></tr><tr><td>Mesostigma viride</td></tr><tr><td>Staurastrum punctulatum</td></tr><tr><td>Zygnema circumcarinatum</td></tr><tr><td>L... | <table><tr><td>Size (bp)</td><td>IR size (bp)</td><td>Genes (no.) a</td><td>Introns (no.) b</td><td>GenBank accession no.</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td>184,933</td><td>10,919</td><td>127</td><td>2/16</td><td>GenBank:NC_008097</td></tr><tr><td>131,183</td><td>12,431</td><td>125</... |
4726a7749ed05fac64b7a00b16b63edcb8474a09416406486c3989f1c40865af.png | simple | <table><tr><td></td><td>N-starved cells</td><td>P-starved cells</td></tr><tr><td>Total sequences collected</td><td>2,259,219</td><td>1,501,972</td></tr><tr><td>Total signatures</td><td>44,779</td><td>27,722</td></tr><tr><td>Reliable, significant signatures</td><td>27,217</td><td>20,161</td></tr><tr><td>Signatures uniqu... | <table><tr><td></td><td>N-starved cells</td><td>P-starved cells</td></tr><tr><td>Total sequences collected</td><td>2,259,219</td><td>1,501,972</td></tr></table> | <table><tr><td></td><td>N-starved cells</td><td>P-starved cells</td></tr><tr><td>Total signatures</td><td>44,779</td><td>27,722</td></tr><tr><td>Reliable, significant signatures</td><td>27,217</td><td>20,161</td></tr><tr><td>Signatures unique to library</td><td>10,756</td><td>3,700</td></tr></table> |
3458bc2bf3406d0cf5e599a6c9345768822978e835d08c400a1490aef1d720d2.png | simple | <table><tr><td></td><td>All patients (<i>n =</i> 129)</td><td>Trastuzumab-resistant patient (<i>n =</i> 32)</td><td>Trastuzumab-sensitive patients (<i>n =</i> 97)</td><td><i>P</i>-value</td></tr><tr><td>Age at diagnosis</td><td>59 (30-84)</td><td>60 (30-82)</td><td>58 (32-84)</td><td>0.623</td></tr><tr><td>Sex</td><td>... | <table><tr><td></td><td>All patients (n = 129)</td></tr><tr><td>Age at diagnosis</td><td>59 (30-84)</td></tr><tr><td>Sex</td><td></td></tr><tr><td>Male</td><td>96 (74.4%)</td></tr><tr><td>Female</td><td>33 (25.6%)</td></tr><tr><td>Histology</td><td></td></tr><tr><td>Adeno, WD</td><td>7 (5.4%)</td></tr><tr><td>Adeno, MD... | <table><tr><td>Trastuzumab-resistant patient (n = 32)</td><td>Trastuzumab-sensitive patients (n = 97)</td><td>P-value</td></tr><tr><td>60 (30-82)</td><td>58 (32-84)</td><td>0.623</td></tr><tr><td></td><td></td><td>0.931</td></tr><tr><td>24 (75.0%)</td><td>72 (74.2%)</td><td></td></tr><tr><td>8 (25.0%)</td><td>25 (25.8%... |
ec52e56d699489f62246126c30ba81107ed7e26921c4e60f9d82bb19979b6478.png | simple | <table><tr><td></td><td>CKD (<i>n</i>= 6)</td><td>CKD + pravastatin (<i>n</i>= 5)</td></tr><tr><td>Focal glomerulosclerosis (%)</td><td></td><td></td></tr><tr><td> Normal</td><td>32.9 ± 7.6</td><td>23.4 ± 13.1</td></tr><tr><td> Partial</td><td>48.1 ± 10.6</td><td>62.7 ± 10.4</td></tr><tr><td> Total<... | <table><tr><td></td></tr><tr><td>Focal glomerulosclerosis (%)</td></tr><tr><td>Normal</td></tr><tr><td>Partial</td></tr><tr><td>Total</td></tr><tr><td>Tubulo-interstitial damage</td></tr><tr><td>Fibrosis</td></tr><tr><td>Inflammation</td></tr><tr><td>Atrophy</td></tr></table> | <table><tr><td>CKD (n= 6)</td><td>CKD + pravastatin (n= 5)</td></tr><tr><td></td><td></td></tr><tr><td>32.9 ± 7.6</td><td>23.4 ± 13.1</td></tr><tr><td>48.1 ± 10.6</td><td>62.7 ± 10.4</td></tr><tr><td>19.0 ± 6.7</td><td>14.0 ± 15.8</td></tr><tr><td></td><td></td></tr><tr><td>0.78 ± 0.31</td><td>0.85 ± 0.14</td></tr><tr>... |
8c042be04cfcbdfe8303b20069e72ee8f551034c1fcc9512ff23b13b33b2afa7.png | complex | <table><tr><td>Dependent variables:</td><td colspan="2">Complaints of generalised anxiety</td></tr><tr><td></td><td>MEN</td><td>WOMEN</td></tr><tr><td></td><td>B</td><td>B</td></tr><tr><td>Intercept</td><td>-0.027 ***</td><td>-0.004</td></tr><tr><td>Contextual effects</td><td></td><td></td></tr><tr><td>Unemployment rat... | <table><tr><td>Dependent variables:</td><td colspan="2">Complaints of generalised anxiety</td></tr><tr><td></td><td>MEN</td><td>WOMEN</td></tr><tr><td></td><td>B</td><td>B</td></tr><tr><td>Intercept</td><td>-0.027 ***</td><td>-0.004</td></tr><tr><td>Contextual effects</td><td></td><td></td></tr><tr><td>Unemployment</td... | <table><tr><td> rate</td><td></td><td>0.075</td></tr><tr><td>Median area income (in euros)</td><td>0.245</td><td>1.214</td></tr><tr><td>Density</td><td>-0.081</td><td>0.032</td></tr><tr><td>Individual effects</td><td></td><td></td></tr><tr><td>Social support</td><td>-0.018 ***</td><td>-0.028 ***</td></tr><tr><td>Curren... |
74d200590c3ca1ffb3a787fa3d8dc0d5e130fc4eb37b98c32f7a256587f624e5.png | simple | <table><tr><td>Year</td><td>First Author</td><td>No</td><td>Sex</td><td>Age</td><td>Site</td><td>Complications</td><td>Treatment</td><td>Incision</td><td>LOS (days)</td></tr><tr><td>1991 [13]</td><td>Hale</td><td>22</td><td>M</td><td>85</td><td>Sigmoid</td><td>Incarceration</td><td>Hartmann’s + intra-abdominal in... | <table><tr><td>Year</td><td>First Author</td><td>No</td><td>Sex</td><td>Age</td><td>Site</td><td>Complications</td><td>Treatment</td><td>Incision</td><td>LOS (days)</td></tr><tr><td>1991 [13]</td><td>Hale</td><td>22</td><td>M</td><td>85</td><td>Sigmoid</td><td>Incarceration</td><td>Hartmann’s + intra-abdominal internal... | <table><tr><td>2017 [25]</td><td>Sharma</td><td>37</td><td>M</td><td>84</td><td>Caecum</td><td>None</td><td>Open right hemicolectomy + herniorrhaphy</td><td>Right transverse</td><td>NA</td></tr><tr><td>2018</td><td>Current report</td><td>38</td><td>M</td><td>83</td><td>Ascending colon</td><td>Incarceration</td><td>Lapa... |
ab132861fa58245909a6e4bed997205f54e00913ff46f5332ed2a53c1b54acbf.png | complex | <table><tr><td></td><td>Normotensive pregnancy (<i>n</i> = 3183)</td><td>Gestational hypertension (<i>n</i> = 145) Beta (95% CI)</td><td><i>P</i> value</td><td>Pre-eclampsia (<i>n</i> = 63) Beta (95% CI)</td><td><i>P</i> value</td></tr><tr><td colspan="6">Retinal arteriolar caliber (SDS)</td></tr><tr><td> Full model</t... | <table><tr><td></td></tr><tr><td>Retinal arteriolar caliber (SDS)</td></tr><tr><td>Full model</td></tr><tr><td>Retinal venular caliber (SDS)</td></tr><tr><td>Full model</td></tr></table> | <table><tr><td>Normotensive pregnancy (n = 3183)</td><td>Gestational hypertension (n = 145) Beta (95% CI)</td><td>P value</td><td>Pre-eclampsia (n = 63) Beta (95% CI)</td><td>P value</td></tr><tr><td colspan="5">Retinal arteriolar caliber (SDS)</td></tr><tr><td>Ref</td><td>–0.20 (–0.34, –0.05)</td><td>0.007</td><td>–0.... |
42680961659dac59e806ee0123b21dbf4f937d94eb9c3464598c90a57e2510ea.png | complex | <table><tr><td rowspan="2">Medium</td><td colspan="5">Time</td></tr><tr><td>0 day</td><td>1 day</td><td>3 days</td><td>5 days</td><td>7 days</td></tr><tr><td>Water</td><td>208.7 ± 12.6</td><td>214.2 ± 10.1</td><td>217.7 ± 9.5</td><td>224.4 ± 10.6</td><td>227.8 ± 13.4</td></tr><tr><td>PBS plus 1... | <table><tr><td rowspan="2">Medium</td><td colspan="5">Time</td></tr><tr><td>0 day</td><td>1 day</td><td>3 days</td><td>5 days</td><td>7 days</td></tr></table> | <table><tr><td>Water</td><td>208.7 ± 12.6</td><td>214.2 ± 10.1</td><td>217.7 ± 9.5</td><td>224.4 ± 10.6</td><td>227.8 ± 13.4</td></tr><tr><td>PBS plus 10% (v/v) FBS</td><td>254.5 ± 5.7</td><td>260.1 ± 4.5</td><td>279.6 ± 7.7</td><td>288.9 ± 10.2</td><td>302.5 ± 9.8</td></tr><tr><td>PBS</td><td>286.6 ± 18.5</td><td>310.... |
d67d7d72921715cd03914076708168d36d3d598a24d008ab27c2af03af91cb56.png | complex | <table><tr><td>Cell lines</td><td colspan="4">IC50</td></tr><tr><td></td><td>GEM (μM)</td><td>OSI-027 (μM)</td><td>OSI-027 (μM) + GEM (μM)</td><td>Interaction</td></tr><tr><td>Panc-1</td><td>14.79 (10.34 to 19.20)</td><td>21.93 (17.37 to 26.48)</td><td>OSI8.951 (8.309 to 9.594)GEM0.8951 (0.8309 to 0... | <table><tr><td>Cell lines</td><td colspan="4">IC50</td></tr><tr><td></td><td>GEM (μM)</td><td>OSI-027 (μM)</td><td>OSI-027 (μM) + GEM (μM)</td><td>Interaction</td></tr></table> | <table><tr><td>Panc-1</td><td>14.79 (10.34 to 19.20)</td><td>21.93 (17.37 to 26.48)</td><td>OSI8.951 (8.309 to 9.594)GEM0.8951 (0.8309 to 0.9594)</td><td>0.465 synergy</td></tr><tr><td>BxPC-3</td><td>0.7716 (0.6574 to 1.356)</td><td>8.551 (7.913 to9.187)</td><td>OSI 3.041 (2.799 to9.594)GEM 0.3041 (0.279 to 0.959)</td>... |
4413ef9a1fe09853a4c51393d92cd339a0f54f3336cd8914cb0c9526d2361b2c.png | simple | <table><tr><td>Statistical value </td><td>DR: VC</td><td>DR: RMSSD</td><td>DR: max-min</td><td>VR</td><td>Rest: VC</td><td>Rest: RMSSD</td><td>DR: max/min</td><td>PI</td></tr><tr><td>Ancova F</td><td>10.854</td><td>8.492</td><td>9.016</td><td>0.380</td><td>6.512</td><td>0.493</td><td>6.467</td><td>2.70</td></tr><tr><td... | <table><tr><td>S</td><td>DR: V</td><td></td><td>D</td><td></td><td>Rest: V</td><td>Re</td><td>D</td><td>PI</td></tr></table> | <table><tr><td>tatistical value</td><td>C</td><td>DR: RMSSD</td><td>R: max-min</td><td>VR</td><td>C</td><td>st: RMSSD</td><td>R: max/min</td><td></td></tr><tr><td>Ancova F</td><td>10.854</td><td>8.492</td><td>9.016</td><td>0.380</td><td>6.512</td><td>0.493</td><td>6.467</td><td>2.70</td></tr><tr><td>p-value</td><td><0.... |
7cd58f259919390bef4a9b742061d74f296e4937b2e3608de6822f9ffcb338b6.png | complex | <table><tr><td>Target<sup>a</sup></td><td>Nucleotide sequence (5′ to 3′)</td><td>Amplicon size (bp)</td><td>Reference</td></tr><tr><td rowspan="2"><i>cfb</i><sup>b</sup></td><td>F: CACACATGCTGTTGGAGTTCAGTTGA</td><td rowspan="2">138</td><td>This study</td></tr><tr><td>R: ACGAAGTCGACAGCATCACACGAAA</td><td></t... | <table><tr><td>Targeta</td><td>Nucleotide sequence (5′ to 3′)</td></tr><tr><td rowspan="2">cfbb</td><td>F: CACACATGCTGTTGGAGTTCAGTTGA</td></tr><tr><td>R: ACGAAGTCGACAGCATCACACGAAA</td></tr><tr><td rowspan="2">erm(A)/(TR)</td><td>F: CCGGCAAGGAGAAGGTTATAATGA</td></tr><tr><td>R: GCATTCACCCGTTGACTCATTTCC</td></tr><tr><td r... | <table><tr><td>Amplicon size (bp)</td><td>Reference</td></tr><tr><td rowspan="2">138</td><td>This study</td></tr><tr><td></td></tr><tr><td rowspan="2">190</td><td>Otaguiri et al. [5]</td></tr><tr><td></td></tr><tr><td rowspan="2">117</td><td>Otaguiri et al. [5]</td></tr><tr><td></td></tr><tr><td rowspan="2">225</td><td... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.